[go: up one dir, main page]

EP1144404A1 - Piperidinylquinolines as protein tyrosine kinase inhibitors - Google Patents

Piperidinylquinolines as protein tyrosine kinase inhibitors

Info

Publication number
EP1144404A1
EP1144404A1 EP00902605A EP00902605A EP1144404A1 EP 1144404 A1 EP1144404 A1 EP 1144404A1 EP 00902605 A EP00902605 A EP 00902605A EP 00902605 A EP00902605 A EP 00902605A EP 1144404 A1 EP1144404 A1 EP 1144404A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
hydroxy
formula
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00902605A
Other languages
German (de)
French (fr)
Inventor
David Thomas SmithKline Beecham Pharm. DAVIES
Caroline Joan SmitKline Beecham Pharm. HENRY
Neil David SmithKline Beecham Pharm. PEARSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901236.1A external-priority patent/GB9901236D0/en
Priority claimed from GBGB9923936.0A external-priority patent/GB9923936D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1144404A1 publication Critical patent/EP1144404A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • This invention relates to novel medicaments, being novel antibacterial compounds and compositions.
  • WO9217475, WO9802438, WO9703069 and WO9639145 disclose certain bicyclic heteroaromatic compounds having cholinesterase inhibitor, protein tyrosine kinase inhibitor, cell proliferation inhibitor and human epidermal growth factor receptor type 2 inhibitor activity.
  • This invention provides a method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment of an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof:
  • Z 1 , Z 2 , Z 3 , Z 4 and Z 5 is N or CR l a and the remainder are CH;
  • R! is selected from hydroxy; (C . ⁇ ) alkoxy optionally substituted by (C ⁇ _6)alkoxy, amino, piperidyl, guanidino or amidino optionally N-substituted by one or two (C ⁇ _ 6)alkyl, acyl or (C ⁇ _6)alkylsulphonyl groups, NH2CO, hydroxy, thiol, (C ⁇ _6)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (Ci .
  • R ⁇ a is selected from hydrogen and the groups listed above for R* ;
  • R3 is in the 2- or 3-position and is: carboxy; (Cj_6)alkoxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C ⁇ _6)alkyl, hydroxy(C ⁇ _6)alkyl, (C2- g)alkenyl, (C ⁇ _6)alkylsulphonyl, trifluoromethylsulphonyl, (C ⁇ _6)alkenylsulphonyl, (Ci .
  • R 4 is a group -CH2-R ⁇ in which R ⁇ is selected from:
  • n 0, 1 or 2;
  • A-B is NHC(O)NH or NHC(O)O, or
  • A is NR 1 1, O, S(O) x or CR 6 R 7 and B is NR 1 1, O, S(O) x or CR 8 R 9 where x is 0, 1 or 2 and wherein: each of R ⁇ and R 7 R 8 and R 9 is independently selected from: H; thiol; (C ⁇ _6)alkylthio; halo; trifluoromethyl; azido; (C ⁇ ..6)alkyl; (C2-6)alkenyl; (C ⁇ _6)alkoxycarbonyl; (C ⁇ _
  • a and B cannot both be selected from NR ⁇ A O and S(O) x and when one of A and B is CO the other is not CO, O or S(O) x .
  • the invention provides a method according to the invention wherein in compounds of formula (I) Rl and R ⁇ a are selected from the groups listed above other than trifluoromethyl.
  • the invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.
  • the invention also provides a pharmaceutical composition for use in the treatment of bacterial infections in mammals comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for use in the treatment of bacterial infections in mammals comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
  • Z 5 is CH or N and Z -Z 4 are each CH.
  • R! or R a is substituted alkoxy it is preferably C2-6 alkoxy substitituted by optionally N-substituted amino, guanidino or amidino, or C ⁇ _6alkoxy substituted by piperidyl.
  • R* alkoxy examples include methoxy, n-propyloxy, i-butyloxy, aminoethyloxy, aminopropyloxy, aminopentyloxy, guanidinopropyloxy, piperidin-4- ylmethyloxy, phthalimido pentyloxy or 2-aminocarbonylprop-2-oxy.
  • R* is methoxy, amino- or guanidino-(C3_5)alkyloxy, guanidino(C3_5)alkyloxy, pi ⁇ eridyl(C3_ 5)alkyloxy, nitro or fluoro, most preferably methoxy.
  • R a is preferably hydrogen.
  • R3 preferably contains carboxy, cyano or 2-oxo-oxazolidinyl optionally substituted by R 10 .
  • R 3 is substituted alkyl is it preferably substituted methyl.
  • R 3 include CO 2 H, CH 2 CO H, (CH 2 )2CO 2 H, (CH 2 )2CN, CONH 2 ,
  • R 3 is preferably in the 3-position. R 3 is most preferably CH2CO2H or 2-oxo-oxazolidinyl.
  • A is NH, NCH3, O, CH , CHOH, CH(NH 2 ), C(Me)(OH) or CH(Me).
  • B is CH 2 , CHOH or CO.
  • n is 0 or 1. More preferably: when A is NH, B is CO and n is 1 or 0; when A is O, B is CH2 and n is 1 or 0; when A is CH2 or CH2OH, B is CH2, and n is 1 or 0; when A is NCH3, CH(NH 2 ), C(Me)(OH) or CH(Me), B is CH 2 and n is 1; when A is CR 6 R 7 and B CR 8 R 9 and R 6 and R 8 together represent -O- and R 7 and R 9 are both hydrogen and n is 1.
  • AB(CH2) n is most preferably (CH2>3.
  • Suitable groups R 4 include n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-dodecyl, methoxybutyl, phenylethyl, phenylpropyl or 3-phenyl-prop-2-en-yl optionally substituted on the phenyl ring, 3-benzoylpropyl, 4-benzoylbutyl, 3-pyridylmethyl, 3-(4- fluorobenzoyl)propyl, cyclohexylmethyl, cyclobutylmethyl, t- butoxycarbonylaminomethyl and phenoxyethyl.
  • R 4 is (C5_ ⁇ o)alkyl, unsubstituted phenyl(C2-3)alkyl or unsubstituted phenyl(C3_4)alkenyl, more preferably hexyl, heptyl, 5-methylhexyl, 6-methyl heptyl, 3- phenyl-prop-2-en-yl or 3-phenylpropyl, most preferably n-heptyl.
  • R ⁇ is unbranched at the ⁇ and, where appropriate, ⁇ positions.
  • Halo or halogen includes fluoro, chloro, bromo and iodo.
  • heterocyclic ' as used herein includes aromatic and non-aromatic, single and fused, rings suitably containing up to four hetero-atoms in each ring selected from oxygen, nitrogen and sulphur, which rings may be unsubstituted or substituted by, for example, up to three groups selected from optionally substituted amino, halogen, (C ⁇ _ 6>alkyl, (C ⁇ _6)alkoxy, halo(C ⁇ _6)alkyl, hydroxy, carboxy, carboxy salts, carboxy esters such as (C ⁇ _6)alkoxycarbonyl, (C ⁇ -6)alkoxycarbonyl(C ⁇ _6)alkyl, aryl, and oxo groups.
  • Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms.
  • a fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.
  • Compounds within the invention containing a heterocyclyl group may occur in two or more tautometric forms depending on the nature of the heterocyclyl group; all such tautomeric forms are included within the scope of the invention.
  • suitable optional substituents in such substituted amino groups include (C ⁇ _6)alkyl optionally substituted by hydroxy, (C ⁇ _6)alkoxy, thiol, (C . 6)alkylthio, halo or trifluoromethyl, and amino-protecting groups such as acyl or (C ⁇ _ 6)alkylsulphonyl groups.
  • lieteroaryr includes the aromatic heterocyclic groups referred to above.
  • heteroaryl groups include pyridyl, triazolyl, tetrazolyl, indolyl, thienyl, isoimidazolyl, thiazolyl, fi ⁇ ranyl,quinolinyl, imidazolidinyl and benzothienyl.
  • the term 'aryl' includes phenyl and naphthyl, each optionally substituted with up to five, preferably up to three, groups selected from halogen, mercapto, (C ⁇ _6)alkyl, phenyl, (C ⁇ _g)alkoxy, hydroxy(C ⁇ _6)alkyl, mercapto (C ⁇ _6)alkyl, halo(C ⁇ _6)alkyl, hydroxy, optionally substituted amino, nitro, carboxy, (Cj. 6)alkylcarbonyloxy, (C ⁇ _6)alkoxycarbonyl, formyl, or (C ⁇ _6)alkylcarbonyl groups.
  • acyl' includes (C ⁇ _6)alkoxycarbonyl, formyl or (Ci -. ⁇ ) alkylcarbonyl group.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (IA), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
  • Some of the compounds of this invention may be crystallised or recrystallised from solvents such as organic solvents. In such cases solvates may be formed.
  • This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation. Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis).
  • Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably from 10 to 59% of a compound of the formula (I) or salt thereof.
  • compositions of the above-mentioned compounds of formula (I) include the free base form or their acid addition or quaternary ammonium salts, for example their salts with mineral acids e.g. hydrochloric, hydrobromic, sulphuric nitric or phosphoric acids, or organic acids, e.g. acetic, fumaric, succinic, maleic, citric, benzoic, p-toluenesulphonic, methanesulphonic, naphthalenesulphonic acid or tartaric acids.
  • Compounds of formula (I) may also be prepared as the N-oxide.
  • Compounds of formula (I) having a free carboxy group may also be prepared as an in vivo hydrolysable ester. The invention extends to all such derivatives.
  • Suitable pharmaceutically acceptable in vivo hydrolysable ester- forming groups include those forming esters which break down readily in the human body to leave the parent acid or its salt. Suitable groups of this type include those of part formulae (i), (ii), (iii), (iv) and (v):
  • R a is hydrogen, (C ⁇ _6) alkyl, (C3.7) cycloalkyl, methyl, or phenyl
  • R ⁇ is (Cj.g) alkyl, (C g) alkoxy, phenyl, benzyl, (C3.7) cycloalkyl, (C3-.7) cycloalkyloxy, (C ⁇ _6) alkyl (C3.7) cycloalkyl, 1-amino (C . ) alkyl, or l-(C ⁇ _6 alkyl)amino (C ⁇ . ) alkyl; or R a and R D together form a 1,2-phenylene group optionally substituted by one or two methoxy groups; R c represents ( .
  • alkylene optionally substituted with a methyl or ethyl group and R ⁇ and R e independently represent (C ⁇ . ) alkyl;
  • R ⁇ represents (C . ) alkyl;
  • RS represents hydrogen or phenyl optionally substituted by up to three groups selected from halogen, (C ⁇ ) alkyl, or (C ⁇ . ) alkoxy;
  • Q is oxygen or NH;
  • R* 1 is hydrogen or (C _£) alkyl;
  • R 1 is hydrogen, (C g) alkyl optionally substituted by halogen, (C2-6) alkenyl, (C .
  • R* 1 and R 1 together form (Cj.g) alkylene;
  • R) represents hydrogen, (C ⁇ . ) alkyl or (C . ) alkoxycarbonyl; and
  • R ⁇ represents (C ⁇ .g) alkyl, (C ⁇ . ⁇ ) alkoxy, (C ⁇ . ) alkoxy(C ⁇ _6)alkoxy or aryl.
  • Suitable in vivo hydrolysable ester groups include, for example, acyloxy(C ⁇ _6)alkyl groups such as acetoxymethyl, pivaloyloxymethyl, ⁇ -acetoxyethyl, ⁇ -pivaloyloxyethyl, l-(cyclohexylcarbonyloxy)prop-l-yl, and (l-aminoethyl)carbonyloxymethyl; (Cj.6)alkoxycarbonyloxy(C ⁇ _6)alkyl groups, such as ethoxycarbonyloxymethyl, ⁇ -ethoxycarbonyloxyethyl and propoxycarbonyloxyethyl; di(C ⁇ _6) a ⁇ yla ⁇ ino(C ⁇ _6)alkyl especially di(C ⁇ _4)alkylamino(C ⁇ _4)alkyl groups such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethy
  • a further suitable pharmaceutically acceptable in vivo hydrolysable ester-forming group is that of the formula:
  • R ⁇ is hydrogen, C ⁇ . alkyl or phenyl.
  • R is preferably hydrogen.
  • Certain of the above-mentioned compounds of formula (I) may exist in the form of optical isomers, e.g. diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures.
  • the invention includes all such forms, in particular the pure isomeric forms.
  • the invention includes compound in which an A-B group CH(OH)-CH2 is in either isomeric configuration, the R-isomer is preferred.
  • the different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.
  • TT-T? are Z ⁇ -Z ⁇ or groups convertible thereto
  • R ⁇ , R* , R , R 3 ' and R 4 ' are R! 1, Rl, R 2 , R 3 and R 4 or groups convertible thereto, and thereafter optionally or as necessary converting R 1 *', R 1 ' , R 2 ', R 3 ' and R 4 ' to R 1 1 R 1 , R 2 , R 3 and R 4 , converting Z 1 -Z 5 ' to Z!-Z 5 , converting A-B to other A-B, interconverting R 1 A R , R 2 , R 3 and/or R 4 and forming a pharmaceutically acceptable derivative thereof.
  • Process variant (a)(iii) and (c) in other aspects initially produces compounds of formula (I) wherein A-B is CH 2 CHOH or CHOHCH 2 .
  • Process variant (a)(iv) initially produces compounds of formula (I) wherein A-B is CH 2 CHOH. .
  • Process variant (a)(x) initially produces compounds of formula (I) wherein A-B is CONHRl l or NHRl lCO.
  • Process variant (a)(xi) initially produces compounds of formula (I) wherein one of A and B is CH2 and the other is NHR 1 1 , O or S.
  • Process variant (a)(xiii) initially produces compounds of formula (I) wherein A-B is OCH 2 or CH O.
  • Process variant (a)(xiv) initially produces compounds of formula (I) where A-B is NHC(O)NH or NHC(O)O.
  • Process variant (b) initially produces compounds of formula (I) wherein A is CH2 and B is NHR 1 1 or O.
  • M is preferably an alkali metal, more preferably Li.
  • the reaction is conducted in an aprotic solvent preferably THF, ether or benzene at -78 to 25°C.
  • An analogous route is described in G. Grethe et al (1972) Helv. Chimica.Acta., 55, 1044.
  • the process is two step: firstly a condensation using a base, preferably sodium hydride or alkoxide, sodamide, alkyl lithium or lithium dialkylamide, preferably in an aprotic solvent e.g. ether, THF or benzene; secondly, hydrolysis using an inorganic acid, preferably HC1 in aqueous organic solvent at 0- 100°C.
  • a base preferably sodium hydride or alkoxide, sodamide, alkyl lithium or lithium dialkylamide
  • an aprotic solvent e.g. ether, THF or benzene
  • hydrolysis using an inorganic acid preferably HC1 in aqueous organic solvent at 0- 100°C.
  • a base is preferably NaH, KH, an alkyl lithium e.g. BuLi, a metal alkoxide e.g. NaOEt, sodamide or lithium dialkylamide e.g.di- isopropylamide.
  • an analogous method is described in US 3989691 and in Taylor et al. (1972) JACS 94, 6218)
  • the reaction is carried out in the presence of a base, preferably organometallic or metal hydride e.g. NaH, lithium diisopropylamide or NaOEt, preferably in an aprotic solvent, preferably THF, ether or benzene at -78 to 25°C (analogous process in Gutswiller et al. (1978) JACS 100, 576).
  • a base preferably organometallic or metal hydride e.g. NaH, lithium diisopropylamide or NaOEt
  • an aprotic solvent preferably THF, ether or benzene
  • reaction is carried out in the presence of a base, preferably organometallic or metal hydride e.g. NaH, lithium diisopropylamide or NaOEt, preferably in an aprotic solvent, preferably THF, ether or benzene at -78 to 25°C.
  • a base preferably organometallic or metal hydride e.g. NaH, lithium diisopropylamide or NaOEt
  • an aprotic solvent preferably THF, ether or benzene at -78 to 25°C.
  • process variant (a)(vi) a similar Claisen methodology to that described for (a)(ii) is used, analogous to that described in Soszko et. al., Pr. Kom.Mat. Przyr.Poznan.Tow.Przyj.Nauk., (1962), 10, 15.
  • a base it is preferably NaH, KH, an alkyl lithium e.g. BuLi, a metal alkoxide e.g. NaOEt, sodamide or lithium dialkylamide e.g.di- isopropylamide.
  • An analogous method is described in US 3989691 and M. Gates et. al.
  • reaction is carried out using palladium catalysis.
  • the palladium catalyst is preferably palladium acetate in the presence of trialkyl or triaryl phosphine and a trialkylamine e.g. triphenyl phosphine and tributylamine.
  • trialkyl or triaryl phosphine and a trialkylamine e.g. triphenyl phosphine and tributylamine.
  • the acid and amide are preferably reacted in the presence of an activating agent such as l-(dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (EDC) or 1-hydroxybenzotriazole (HOBT),
  • an activating agent such as l-(dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (EDC) or 1-hydroxybenzotriazole (HOBT)
  • a final reduction step provides the required amine.
  • the reaction is a standard amine formation reaction such as direct alkylation described in (Malpass, J. R., in Comprehensive Organic Chemistry, Vol. 2 (Ed. Sutherland, I. O.), p 4 ff.) or aromatic nucleophilic displacement reactions (see references cited in Comprehensive Organic Chemistry, Vol. 6, p 946-947 (reaction index); Smith, D. M. in Comprehensive Organic Chemistry, Vol. 4 (Ed. Sammes, P. G.) p 20 ff.). This is analogous to the methods described in GB 1177849.
  • reaction is a standard reductive alkylation using, e.g., sodium triacetoxyborohydride (Gribble, G. W. in Encyclopedia of Reagents for Organic Synthesis (Ed. Paquette, L. A.) (John Wiley and Sons, 1995), p 4649).
  • sodium triacetoxyborohydride Gribble, G. W. in Encyclopedia of Reagents for Organic Synthesis (Ed. Paquette, L. A.) (John Wiley and Sons, 1995), p 4649.
  • reaction variant (a)(xiv) the reaction of the compounds of formulae (IV) and (V) is a standard urea or carbamate formation reaction conducted by methods well known to those skilled in the art (for example see March, J; Advanced Organic Chemistry, Edition 3 (John Wiley and Sons, 1985)).
  • the process is preferably carried out in a polar, non-nucleophilic solvent such as N,N-dimethylformamide.
  • the rearrangement may be effected by treatment with an acid, preferably an organic acid such as acetic acid and the reaction temperature is 80- 120°C.
  • an acid preferably an organic acid such as acetic acid and the reaction temperature is 80- 120°C.
  • the compound of formula (II) is quaternised by treatment with an alkylating agent and treated with base such as KOH to give, depending upon the stereochemistry of the OH and the nature of the quaternery salt and base, either the ketone of formula (HI) or an epoxide which can be opened to the alcohol of formula (VII by reduction (see EP0035821 ).
  • the reaction is preferably carries out in an alcohol, preferably methanol under irradiation conditions which are known to generate singlet oxygen as described in M. Ihara et.al. (1988), J.Chem Soc Perkin Trans. 1, 1277.
  • Reduction of A or B CO to CHOH can be readily accomplished using reducing agents well known to those skilled in the art, e.g. sodium borohydride in aqueous ethanol or lithium aluminum hydride in ethereal solution.. This is analogous to methods described in EP 53964, US 384556 and J. Gutzwiller et. al. (1978) J.Amer.Chem.Soc, 100, 576.
  • the carbonyl group A or B may be reduced to CH2 by treatment with a reducing agent such as hydrazine in ethylene glycol at 130-160°C in the presence of potassium hydroxide.
  • a reducing agent such as hydrazine in ethylene glycol at 130-160°C in the presence of potassium hydroxide.
  • Reaction of a carbonyl group A or B with an organometallic reagent yields a group where R 6 or R 8 is OH and R 7 or R 9 is alkyl.
  • a hydroxy group in A or B may be oxidised to a carbonyl group by oxidants well known to those skilled in the art , for example, manganese dioxide, pyridinium chlorochromate or pyridinium dichromate.
  • An A-B group COCH2 may be converted to COCH-halogen, by treating the ketone or a derivative with a halogenating agent, reduced to CHOHCHC1 and then converted to the epoxide which may in turn be reduced to CH2CHOH.
  • An amide group CONHR 1 1 ' or NHR 1 ⁇ CO may be reduced to the amine using a reducing agent such as lithium aluminium hydride
  • a ketone group may be converted to an amide CONH via the oxime by a Beckmann rearrangement (Ogliaruso, M.A.; Wolfe, J. F., ibid, pp 450-451; Beckwith, A. L. I., ibid, pp 131 ff.)
  • a hydroxy group in A or B may be converted to azido by activation and displacement e.g. under Mitsunobu conditions using hydrazoic acid or by treatment with diphenylphosphorylazide and base, and the azido group in turn may be reduced to amino by hydrogenation.
  • a sulphur group A or B may be converted to the sulphoxide S(O) x by oxidation with peracids or a wide range of oxidants known to those skilled in the art (see Advanced Organic Chemistry (Ed. March, J.) (John Wiley and Sons, 1985), p 1089 and refs. cited therein).
  • R 1 ', R 2 ', R 3 ' and R 4 ' are preferably R 1 , R 2 , R 3 and R 4 .
  • R 1 ' is preferably methoxy.
  • R 2 ' is preferably hydrogen.
  • R 3 ' is preferably vinyl or contains a carboylate ester group.
  • R 4 ' is preferably H, R 4 or a protecting group.
  • R 1 ', R 2 ', R 3 ' and R 4 ' and interconversions of R 1 , R 2 , R 3 and R 4 are conventional.
  • suitable conventional hydroxy protecting groups which may be removed without disrupting the remainder of the molecule include acyl and alkylsilyl groups.
  • R 1 ' methoxy is convertible to R 1 ' hydroxy by treatment with lithium and diphenylphosphine (general method described in Ireland et. al. (1973) J.Amer.Chem.Soc.,7829) or HBr.
  • Z 1 -Z ⁇ ' examples are CR l a ' where R l a ' is a group convertible to R l a .
  • R 3 ' alkenyl is convertible to hydroxyalkyl by hydroboration using a suitable reagent such as 9-borabicyclo[3.3.1]nonane, epoxidation and reduction or oxymercuration.
  • R 3 ' 1 ,2-dihydroxy can be prepared from R 3' alkenyl using osmium tetroxide or other reagents well known to those skilled in the art (see Advanced Organic Chemistry (Ed. March, J.) (John Wiley and Sons, 1985), p 732-737 and refs.
  • Opening an epoxide-containing R 3 ' group with azide anion yields an azide derivative which can be reduced to the amine. Conversion of the amine to a carbamate is followed by ring closure with base to give the 2-oxo-oxazolidinyl containing R 3 group.
  • Substituted 2-oxo-oxazolidinyl containing R 3 groups may be prepared from the corresponding aldehyde by conventional reaction with a glycine anion equivalent, followed by cyclisation of the resulting amino alcohol (M Grauert et al, Ann Chem (1985) 1817, Rozenberg et al, Angew Chem Int Ed Engl (1994) 33(1) 91). The resulting 2-oxo- oxazolidinyl group contains a carboxy group which can be converted to other R 1 ⁇ groups by standard procedures.
  • Carboxy groups within R3 may be prepared by Jones' oxidation of the corresponding alcohols CH2OH using chromium acid and sulphuric acid in water/methanol (E.R.H. Jones et al, J.C.S. 1946,39).
  • Other oxidising agents may be used for this transformation such as sodium periodate catalysed by ruthenium trichloride (G.F.Tutwiler et al, J.Med.Chem., 1987, 30(6), 1094), chromium trioxide-pyridine (G. Just et al, Synth. Commun. 1979, 9(7), 613), potassium permanganate (D.E.Reedich et al, J. Org. Chem.,1985,50(19),3535, and pyridinium chlorochromate (D. Askin et al, Tetrahedron Letters, 1988, 29(3), 277.
  • the carboxy group may alternatively be formed in a two stage process, with an initial oxidation of the alcohol to the corresponding aldehyde using for instance dimethyl sulphoxide activated with oxalyl chloride (N.Cohen etal, J. Am. Chem. Soc, 1983, 105, 3661) or dicyclohexylcarbodiimide (R.M.Wengler, Angew. Chim. Int. Ed. Eng., 1985, 24(2), 77), or oxidation with tetrapropylammonium perruthenate (Ley et al, J. Chem.Soc. Chem Commun., 1987, 1625).
  • dimethyl sulphoxide activated with oxalyl chloride N.Cohen etal, J. Am. Chem. Soc, 1983, 105, 3661
  • dicyclohexylcarbodiimide R.M.Wengler, Angew. Chim. Int. Ed. Eng
  • the aldehyde may then be separately oxidised to the corresponding acid using oxidising agents such as silver (H) oxide (R.Grigg et al, J. Chem. Soc. Perkinl,1983, 1929), potassium permanganate (A.Zurcher, Helv. Chim. Acta., 1987, 70 (7), 1937), sodium periodate catalysed by ruthenium trichloride (T.Sakata et al, Bull. Chem. Soc. Jpn., 1988, 61(6), 2025), pyridinium chlorochromate (R.S.Reddy et al, Synth. Commun., 1988, 18(51), 545) or chromium trioxide (R.M.Coates et al, J. Am. Chem. Soc, 1982, 104, 2198).
  • oxidising agents such as silver (H) oxide (R.Grigg et al, J. Chem. Soc. Perkinl,1983, 1929), potassium per
  • R 3 CO2H group may also be prepared from oxidative cleavage of the corresponding diol, CH(OH)CH2OH, using sodium periodate catalysed by ruthenium trichloride with an acetontrile-carbontetrachloride- water solvent system (V.S.Martin et al, Tetrahedron Letters, 1988, 29(22), 2701).
  • R 3 groups containing a cyano or carboxy group may also be prepared by conversion of an alcohol to a suitable leaving group such as the corresponding tosylate by reaction with para-toluenesulphonyl chloride (M.R.Bell, J. Med. Chem., 1970, 13, 389), or the iodide using triphenylphosphine, iodine, and imidazole (G. Lange, Synth. Commun., 1990, 20, 1473).
  • the second stage is the displacement of the leaving group with cyanide anion (LA.Paquette et al, J. Org. Chem.,1979, 44 (25), 4603; P.A.Grieco et al, J. Org.
  • the tetrazol-5-ylaminocarbonyl group may be prepared from the corresponding carboxylic acid and 2-aminotetrazole by dehydration with standard peptide coupling agents such as l,l'-carbonyldiimidazole (P. L. Ornstein et al, J. Med Chem, 1996, 39 (11), 2232).
  • the alkyl- and alkenyl-sulphonylcarboxamides are similarly prepared from the corresponding carboxylic acid and the alkyl- or alkenyl-sulphonamide by dehydration with standard peptide coupling agents such as 1 , 1 -carbonyldiimidazole (P. L. Ornstein et al, J.Med.Chem., 1996, 39 (11), 2232).
  • hydroxamic acid groups are prepared from the corresponding acids by standard amide coupling reactions eg N. R. Patel et al, Tetrahedron, 1987, 43 (22), 5375 2,4-Thiazolidinedione groups may prepared from the aldehydes by condensation with 2,4-thiazolidinedione and subsequent removal of the olefinic double bond by hydrogenation.
  • l,2,4-Triazol-5-yl groups may be prepared from the corresponding nitrile by reaction with an alcohol under acid conditions followed by reaction with hydrazine and then an R ⁇ -substituted activated carboxylic acid (see JB Polya in 'Comprehensive Heterocyclic Chemistry' Edition 1 p762, Ed AR Katritzky and CW Rees, Pergamon Press, Oxford 1984 and J.J. Ares et al, J. Heterocyclic Chem., 1991, 28(5), 1197).
  • R 3 alkyl or alkenyl may be interconverted by conventional methods, for example hydroxy may be derivatised by esterification, acylation or etherification. Hydroxy groups may be converted to halogen, thiol, alkylthio, azido, alkylcarbonyl, amino, aminocarbonyl, oxo, alkylsulphonyl, alkenylsulphonyl or aminosulphonyl by conversion to a leaving group and substitution by the required group or oxidation as appropriate or reaction with an activated acid, isocyanate or alkoxyisocyanate.
  • Primary and secondary hydroxy groups can be oxidised to an aldehyde or ketone respectively and alkyated with a suitable agent such as an organometallic reagent to give a secondary or tertiary alcohol as appropriate.
  • NH is converted to NR 4 by conventional means such as alkylation with an alkyl halide in the presence of base, acylation/reduction or reductive alkylation with an aldehyde.
  • Compounds of formula (II) include quinine and derivatives thereof.
  • Compounds of formula (VI) are known compounds or may be prepared analogously, see for example Ihara et al JCS Perkin 1 1988, 1277-1281.
  • Compounds of formulae (IV), (V) and (Vb) are known compounds, (see for example Smith et al, J. Amer. Chem. Soc, 1946, 68, 1301) or prepared analogously, see for example the references cited above for reaction variant (a).
  • An isocyanate of formula (IV) may be prepared conventionally.
  • a 4-amino derivative such as 4-amino-quinoline, and phosgene, or phosgene equivalent (eg triphosgene) provide the isocyanate or it may be prepared more conveniently from a 4-carboxylic acid by a 'one-pot' Curtius Reaction with diphenyl phosphoryl azide (DPP A) [see T. Shiori et al. Chem. Pharm. Bull. 35, 2698-2704 (1987)].
  • DPP A diphenyl phosphoryl azide
  • the 4-carboxy derivatives are commercially available or may be prepared by conventional procedures for preparation of carboxy heteroaromatics well known to those skilled in the art.
  • quinazolines may be prepared by standard routes as described by T.A. Williamson in Heterocyclic Compounds, 6, 324 (1957) Ed. R.C. Elderfield.
  • Pyridazines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 3, Ed A.J. Boulton and A.
  • McKillop and napthyridines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 2, Ed A.J. Boulton and A. McKillop.
  • the 4-amino derivatives are commercially available or may be prepared by conventional procedures from a corresponding 4-chloro derivative by treatment with ammonia (O.G. Backeberg et. al., J. Chem Soc, 381, 1942.) or propylamine hydrochloride (R. Radinov et. al., Synthesis, 886, 1986).
  • a 4-chloroquinoline is prepared from the corresponding quinolin-4-one by reaction with phosphorus oxychloride (POCl 3 ) or phosphorus pentachloride, PC1 5
  • a 4-chloroquinazoline is prepared from the corresponding quinazolin-4-one by reaction with phosphorus oxychloride (POCl 3 ) or phosphorus pentachloride, PC1 5 .
  • a quinazolinone and quinazolines may be prepared by standard routes as described by T.A. Williamson in Heterocyclic Compounds, 6, 324 (1957) Ed. R.C. Elderfield.
  • Pyridazines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 3, Ed A.J. Boulton and A. McKillop and napthyridines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 2, Ed A.J. Boulton and A. McKillop.
  • 4-Hydroxy-l,5-naphthyridines can be prepared from 3-aminopyridine derivatives by reaction with diethyl ethoxymethylene malonate to produce the 4-hydroxy-3- carboxylic acid ester derivative with subsequent hydrolysis to the acid, followed by thermal decarboxylation in quinoline (as for example described for 4-Hydroxy- [l,5]naphthyridine-3-carboxylic acid, Joe T. Adams et al, J ⁇ mer.Chem.Soc, 1946, 68, 1317).
  • a 4-hydroxy-[l,5]naphthyridine can be converted to the 4-chloro derivative by heating in phosphorus oxychloride.
  • a 4-amino 1 ,5-naphthyridine can be obtained from the 4-chloro derivative by reaction with n-propylamine in pyridine.
  • 6-methoxy-l,5-naphthyridine derivatives can be prepared from 3-amino-6- methoxypyridine.
  • 4-Methyl-l,5-naphthyridines can be prepared by methods well known to those skilled in the art (for example see H. Rapoport and A. D. Batcho, Journal of Organic Chemistry, 1963, 1753-1759). For example, nitrobenzene can be heated with oleum over a period of hours then water and a 3-aminopyridine added with heating. Slow addition of methyl vinyl ketone with heating produces the desired 4-methyl-l,5-naphthyridine.
  • 1,5-Naphthyridines may be prepared by other methods well known to those skilled in the art (for examples see P.A. Lowe in “Comprehensive Heterocyclic Chemistry” Volume 2, p581-627, Ed A.R. Katritzky and CW. Rees, Pergamon Press, Oxford, 1984).
  • the 4-hydroxy and 4-amino-cinnolines may be prepared following methods well known to those skilled in the art [see A.R. Osborn and K. Schofield, J. Chem. Soc. 2100 (1955)].
  • a 2-aminoacetopheneone is diazotised with sodium nitrite and acid to produce the 4- hydroxycinnoline with conversion to chloro and amino derivatives as described for 1 ,5- naphthyridines.
  • a 3-methyl substituent may be introduced by reaction of a 4-chlorocmnohne with lithium diisopropylamide at -75°C followed by alkylation with methyl iodide [see A. Turck et al. Tetrahedron, 47, 13045 ( 1995)].
  • suitable amines may be prepared from the corresponding acid or alcohol (Y is CO2H or CH2OH).
  • Y is CO2H or CH2OH.
  • an N-protected piperidine containing an acid bearing substituent can undergo a Curtius rearrangement and the intermediate isocyanate can be converted to a carbamate by reaction with an alcohol. Conversion to the amine may be achieved by standard methods well known to those skilled in the art used for amine protecting group removal.
  • an acid substituted N-protectedpiperidine can undergo a Curtius rearrangement e.g.
  • an acid group (CH2) n -lCO2H may be converted to (CH2) n NHRj j by reaction with an activating agent such as isobutyl chloro formate followed by an amine R 1 1 NH2 and the resulting amide reduced with a reducing agent such as
  • an N-protected piperidine containing an alcohol bearing substituent undergoes a Mitsunobu reaction (for example as reviewed in Mitsunobu, Synthesis, (1981), 1), for example with succinimide in the presence of diethyl azodicarboxylate and triphenylphosphine to give the phthalimidoethylpiperidine.
  • a Mitsunobu reaction for example as reviewed in Mitsunobu, Synthesis, (1981), 1
  • succinimide in the presence of diethyl azodicarboxylate and triphenylphosphine to give the phthalimidoethylpiperidine.
  • a trans-substituted piperidine moiety of formula (V) may be prepared from the corresponding cis isomer of formula (V) having an R vinyl group in the 3-position with a substituent that can subsequently be converted to the required group (CH2) n Y, for example CH2CO2R
  • R is an alkyl group eg methyl or ethyl
  • compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.
  • the antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics.
  • the composition may be formulated for administration by any route, such as oral, topical or parenteral.
  • the compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • the topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.
  • the formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.
  • Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient.
  • the dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.
  • the compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a ⁇ -lactamase inhibitor may be employed.
  • Example la A solution of Example la(231.5g, 0.71 mol) in ethylene glycol (1.01) was treated with hydrazine hydrate (50g, 1.0 mol) over 0.3 h. The mixture was warmed to 120°C for 1.5h. The mixture was then cooled to 10°C and potassium hydroxide (92.7g) was added and the mixture extracted with dichloromethane (2x). The dichloromethane extracts were washed with brine, dried (Na2SO4), and evaporated affording the title compound as a brown oil (217g, 100%). El MH+ 311 C20H26N2O requires 310.
  • Example 2b The above crude product (Example 2b) was dissolved in ethyl acetate and vigorously stirred with an equal volume of saturated aqueous sodium bicarbonate solution. Benzyl chloroformate (1.3 equivalents) was added and the mixture stirred under argon for 5 h. The phases were separated and the ethyl acetate extract dried and evaporated. The crude material was purified by chromatography eluting with an ethyl acetate/hexane gradient. E.I. MH+ 612, C36H41N3O6 requires 611
  • Example 3b was dissolved in dichloromethane-N,N-dimethylformamide and treated with triethylamine (1.2 eq),di-t-butylcarbonic anhydride (1.1 equivalents ) and N,N-dimethylaminopyridine (catalytic quantity). After stirring overnight the mixture was evaporated and purified by chromatography on silica eluting with a gradient of ethyl acetate/hexane, giving the product as an oil ( 3.8g, 34%)
  • Example 3c (2.2g, 5.1 mmol) was dissolved in dichloromethane (50ml), then triethylamine ( 0.85ml, 0.62g, 6.1 mmol), N,N- dimethylaminopyridine (catalytic) and 4-methylphenylsulfonyl chloride (l.lg, 5.6 mmol) were added. After 20h the mixture was diluted with more dichloromethane and washed with water. The organic extract was dried (Na2SO4) and evaporated. Chromatography on silica eluting with ethyl acetate: hexane (1: 1) afforded the product as a yellow oil ( 1.8g, 61%).
  • Example 3d (1.8g, 31mmol) was dissolved in N,N-dimethylformamide (15ml) and treated with sodium cyanide ( 0.3g, 6.2 mmol). The mixture was stirred at room temperature for 16 h then at 40° for lh. The mixture was evaporated to dryness and the residue was partitioned between ethyl acetate and water. The organic extract was dried (MgSO4) and evaporated to give the product as an oil, (67%). E.I. MH+ 438, C26H35N3O3 requires 437.
  • Example 3f The title compound was prepared from Example 3f by heptylation using the procedure of Example lh, giving the purified product as an oil (0.55g, 62%)
  • Example 1 A solution of Example 1(60 mg, 0.13 mmol) in concentrated hydrochloric acid:dioxane (6 ml:3 ml) was heated to reflux for 4h. The mixture was neutralised with saturated aqueous sodium bicarbonate solution and extracted (3X) with ethyl acetate. The combined organic extracts were dried and evaporated and the crude product chromatographed on silica eluting with aqueous ammonia:methanol:chloroform (1.5:15:50) giving the title compounds as a colourless oil, (0.019g, 30%). E.I. MH+ 471, C28H42N2O3 requires 470.
  • Example 1 A solution of Example 1(48 mg, 0.11 mmol) in concentrated hydrochloric acid:dioxane (5 ml:3 ml) was heated to reflux for 24h. The mixture was neutralised with saturated aqueous sodium bicarbonate solution and extracted (3X) with ethyl acetate. The combined organic extracts were dried and evaporated and the crude product chromatographed on silica eluting with aqueous ammonia:methano:chloroform (1.5:15:50) giving the title compound as a colourless oil, (0.015g, 31%).
  • E.I. MH+ 453, C28H40N2O2 requires 452.
  • the urea (lOe) (0.92g) was treated with dichloromethane (20ml) and trifluoroacetic acid (30ml) at room temperature for 3 hours and evaporated to dryness. It was basified with sodium carbonate solution and evaporated to dryness. The solid was extracted three times with warm ethanol-chloroform (1:9) and evaporated to dryness to afford a foam (0.80g).
  • Example 13b A solution of Example 13b (57g, 140 mmol) in toluene (1 1) was treated with triphenyl phosphine (114g, 440 mmol) and diethylazodicarboxylate (80 ml, 510 mmol). The mixture was heated to reflux for 8h, the cooled and chromatographed eluting with methanol in dichloromethane to give the product as an oil (12g, 22%).
  • El MH + 383 C22H26 2O4 requires 382.
  • Example 12a A solution of Example 12a (12g, 31.4 mmol) in N,N-dimethylformamide (100 ml) was treated with sodium azide (11.7g) and ammonium chloride (lg) and heated at 140° C for 7h. The mixture was evaporated and the residue partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic extract was dried and evaporated. The residue was chromatographed on silica eluting with methanol in dichloromethan affording the title compound as an orange foam (2.03g, 15%).
  • Example 12e(105 mg) in N,N-dimethylformamide (3 ml) was treated with potassium carbonate (0.14g) and heptyl iodide (0.2 ml). After 2h the reaction mixture was diluted with ethyl acetate and washed with sodium carbonate solution, brine, dried and evaporated.
  • Example 12f (42 mg, 0.09 mmol) in 2-propanol (5 ml) wastreated with sodium borohydride (20 mg). After 2h the mixture was diluted with water and extracted with dichloromethane. The organic extract was dried and evaporated. Chromatography on silica eluting with methanol in dichloromethan afforded the title compounds as a clear oil (30 mg, 71%),
  • Example 13d A solution of Example 13d (3.58 g) in glacial acetic acid (4 ml) and water (40 ml) was heated at reflux under a flow of argon for 36 hours. The reaction mixture was taken to pH12 with sodium hydroxide solution. The mixture was extracted into ethyl acetate, dried over anyhydrous magnesium sulphate, filtered and the solvent removed under reduced pressure. Chromatography on silica gel eluting with 5 to 10 % methanol in dichloromethane gave the compound as an oil (0.830 g, 23%).
  • Amine 13e (0.830g) was heptylated according to the method for example lh to give the compound as an oil (0.856g, 80%).
  • Example 14 [3R, 4R]-l-Heptyl-3-cyanomethyl-4-(2-(R)-hydroxy-3-(6- methoxyquinolin-4-yl)propyl]piperidine a) [3R,4R]- 1 -Heptyl-3-cyanomethyl-4-[2(R),3(R)-oxiranyl-3-(6-methoxyquinolin-4- yl)propyl]piperidine A solution of 13d (3.2 g) in toluene (30 ml) and N,N-dimethylformamide (3ml) was heated at 80°C with heptyl bromide( 1.65ml) overnight under a stream of argon.
  • the MIC ( ⁇ g/ml) of test compounds against various organisms was determined: S. aureus Oxford, S. aureus WCUH29, S. aureus Carter 37, E. faecalis I, M. catarrhalis Ravasio, S. pneumoniae R6.
  • Examples 1 to 8, 12 to 14, 18 to 25, 33 and 36 have an MIC of less than or equal to 1 ⁇ g/ml against one or more of the above range of gram positive and gram negative bacteria.
  • Examples 11, 17, 26 to 32, 34 and 35 showed an MIC of less than or equal to 16 ⁇ g/ml against one or more of the above range of gram positive and gram negative bacteria.
  • Examples 9, 10, 15 and 16 showed an MIC of less than or equal to 64 ⁇ g/ml against one or more of the above range of gram positive and gram negative bacteria.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Piperidine derivatives, processes for making them and their use in methods of treatment of bacterial infections in mammals.

Description

PIPERIDINYLQUINOLINES AS PROTEIN TYROSINE KINASE INHI BITORS
This invention relates to novel medicaments, being novel antibacterial compounds and compositions.
WO9217475, WO9802438, WO9703069 and WO9639145 disclose certain bicyclic heteroaromatic compounds having cholinesterase inhibitor, protein tyrosine kinase inhibitor, cell proliferation inhibitor and human epidermal growth factor receptor type 2 inhibitor activity.
This invention provides a method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment of an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof:
(I) wherein:
one of Z1, Z2, Z3, Z4 and Z5 is N or CRl a and the remainder are CH;
R! is selected from hydroxy; (C .β) alkoxy optionally substituted by (Cτ _6)alkoxy, amino, piperidyl, guanidino or amidino optionally N-substituted by one or two (Cι_ 6)alkyl, acyl or (Cι_6)alkylsulphonyl groups, NH2CO, hydroxy, thiol, (Cι_6)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (Ci . 6)alkylsulphonyloxy; (Cι_6)alkoxy-substituted (Cι_6)alkyl; halogen; (Cι_6)alkyl; (Cι _ 6)alkylthio; trifluoromethyl; nitro; azido; acyl; acyloxy; acylthio; (Cι_6)alkylsulphonyl; (Cι_6)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (Cι_6)alkyl, acyl or (Cμ 6)alkylsulphonyl groups, or when one of Z\, 7?-, 7?, Z4 and 7? is N, R* may instead be hydrogen;
R^a is selected from hydrogen and the groups listed above for R* ;
R3 is in the 2- or 3-position and is: carboxy; (Cj_6)alkoxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (Cι_6)alkyl, hydroxy(Cι_6)alkyl, (C2- g)alkenyl, (Cι_6)alkylsulphonyl, trifluoromethylsulphonyl, (Cι_6)alkenylsulphonyl, (Ci . 6)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (C2-6)alkenyloxycarbonyl or (C2- 6)alkenylcarbonyl and optionally further substituted by (Cι _6)alkyl, hydroxy(Cι_6)alkyl, aminocarbonyl(Cιι.6)alkyl or (C2-6)alkenyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R^O; 3-hydroxy-3-cyclobutene-l,2-dione-4-yl; 2,4- thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; l,2,4-triazol-5-yl optionally substituted by RlO; or 5-oxo-l,2,4-oxadiazol-3-yl; or R3 is in the 2- or 3-position and is (C 1 _4)alkyl or ethenyl substituted with any of the groups listed above for R3 and 0 to 2 groups R*2 independently selected from: thiol; halogen; (Cι _6)alkylthio; trifluoromethyl; azido; (Cι _6)alkoxycarbonyl; (Cι_6)alkylcarbonyl; (C2-6)alkenyloxycarbonyl; (C2-6)alkenylcarbonyl; hydroxy optionally substituted by (Cι _6)alkyl, (C2_6)alkenyl, (Cι _6)alkoxycarbonyl, (C{_ 6)alkylcarbonyl, (C2-6)alkenyloxycarbonyl, (C2-6")alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (Cι _6)alkyl, (C2-6)alkenyl> (Cj. 6)alkylcarbonyl or (C2_6)alkenylcarbonyl; amino optionally mono- or disubstituted by (Cι _6)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (C2-6)alkenyloxycarbonyl, (C2- 6)alkenylcarbonyl, (Cι _6)alkyl, (C2-6)alkenyl, (Cι _6)alkylsulphonyl, (C2- 6)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (Cι _6)alkyl or (C2-6)alkenyl; aminocarbonyl wherein the amino group is optionally substituted by (Cι_(j)alkyl, hydroxy(Cι _6)alkyl, aminocarbonyl(Cιt_6)alkyl, (C2. g)alkenyl, (Cι_6)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (C2-6)alkenyloxycarbonyl or (C2- 6)alkenylcarbonyl and optionally further substituted by (Cι _6)alkyl, hydroxy(Cι_6)alkyl, aminocarbonyl(Cι _6)alkyl or (C2-6)alkenyl; oxo; (Cι _6)alkylsulphonyl; (C2-
6)alkenylsulphonyl; or (Cι_6)aminosulphonyl wherein the amino group is optionally substituted by (C1.g)alkyl or (C2-6)alkenyl; provided that when R3 is disubstituted with hydroxy or amino and carboxy containing substituents these may optionally together form a cyclic ester or amide linkage, respectively; and provided that R3 is other than (Cι_4)alkyl or ethenyl substituted by (C _ 6)alkoxycarbonyl or aminocarbonyl optionally substituted by (Cι_6)alkyl, (C2-6)alkenyl, (Cι _6)alkoxycarbonyl, (Cι _6)alkylcarbonyl, (C2_6)alkenyloxycarbonyl or (C2-. 6)alkenylcarbonyl and optionally further substituted by (Cι_6)alkyl, hydroxy(Cι_6)alkyl, aminocarbonyl(Cι _6)alkyl or (C2-6)aU£enyl and 0 to 2 groups R*2; wherein R 0 is selected from (Cι__ι)alkyl; (C2-4)alkenyl; aryl; a group R^ as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C 6)alkyl, (C2-6)alkenyl, (Cι_6)alkylsulphonyl, trifluoromethylsulphonyl, (Cι_6)alkenylsulphonyl, (Cι_6)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (C2- 6)alkenyloxycarbonyl or (C2-6)alkenylcarbonyl and optionally further substituted by (Cx_ 6)alkyl or (C2-6)alkenyl; cyano; or tetrazolyl;
R4 is a group -CH2-R^ in which R^ is selected from:
(C3.12)alkyl; hydroxy(C3.12)alkyl; (C1.12)alkoxy(C3.i2)alkyl; (Cι_ 12)alkanoyloxy(C3_12)alkyl; (C3_6)cycloalkyl(C3.i2)alkyl; hydroxy-, (Cι_i2)alkoxy- or
(C 1 - 12)alkanoyloxy-(C3_5)cycloalkyl(C3_ \ 2)alkyl; cyano(C3_ 2)alkyl; (C2- 12)alkenyl;
(C2-i2)alkynyl; tetrahydrofuryl; mono- or di-(Cι_ι^)alkylamino(C3_i2)alkyl; acylamino(C3_ιt2)alkyl; mono- or di-
(Cι_i2)alkylamino(hydroxy) (C3_i2)alkyl; optionally substituted phenyl(Cι_2) lkyl, phenoxy(C j _2)alkyl or phenyl(hydroxy)(C _2)alkyl; optionally substituted diphenyl(C \ .
2)alkyl; optionally substituted phenyl(C2-3)alkenyl; optionally substituted benzoyl or benzoylmethyl; optionally substituted heteroaryl(Cι _2)alkyl;and optionally substituted heteroaroyl or heteroaroylmethyl;
n is 0, 1 or 2;
either A-B is NHC(O)NH or NHC(O)O, or
A is NR11, O, S(O)x or CR6R7 and B is NR11, O, S(O)x or CR8R9 where x is 0, 1 or 2 and wherein: each of R^ and R7 R8 and R9 is independently selected from: H; thiol; (Cι_6)alkylthio; halo; trifluoromethyl; azido; (Cι..6)alkyl; (C2-6)alkenyl; (Cι _6)alkoxycarbonyl; (C\_
6)alkylcarbonyl; (C2-6)alkenyloxycarbonyl; (C2-6)alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R3; (C\_ o ^kyl^Phonyl; (C2-6)alkenylsulphonyl; or (Cι_6)aminosulphonyl wherein the amino group is optionally substituted by (Cι_6)alkyl or (Cι_6)alkenyl; or R° and R8 together represent a bond and R7 and R9 are as above defined; or R and R& together represent -O- and R7 and R9 are both hydrogen; or R" and R7 or R8 and R9 together represent oxo; and each R 11 is independently H, trifluoromethyl, (C \ _6)alkyl, (C \ _6)alkenyl, (C .
6)alkoxycarbonyl, (Cι_g)alkylcarbonyl, aminocarbonyl wherein the amino group is optionally substituted by (Cι_6)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (Ci _ 6)alkenyloxycarbonyl, (C2-6)alkenylcarbonyl, (Cι_6)alkyl or (Cιt.6)alkenyl and optionally further substituted by (Cιι_6)alkyl or (Cι _6)alkenyl;
provided that A and B cannot both be selected from NR^ A O and S(O)x and when one of A and B is CO the other is not CO, O or S(O)x.
In one aspect the invention provides a method according to the invention wherein in compounds of formula (I) Rl and R^a are selected from the groups listed above other than trifluoromethyl. The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.
The invention also provides a pharmaceutical composition for use in the treatment of bacterial infections in mammals comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier. Preferably Z5 is CH or N and Z -Z4 are each CH.
In a preferred aspect, when A is CH2 or CHOH and B is CH2 or A is CH2 and B is CHOH and n is 1 the substitutents at the 3- and 4-position of the piperidine ring are cis. When R! or R a is substituted alkoxy it is preferably C2-6 alkoxy substitituted by optionally N-substituted amino, guanidino or amidino, or Cι_6alkoxy substituted by piperidyl. Suitable examples of R* alkoxy include methoxy, n-propyloxy, i-butyloxy, aminoethyloxy, aminopropyloxy, aminopentyloxy, guanidinopropyloxy, piperidin-4- ylmethyloxy, phthalimido pentyloxy or 2-aminocarbonylprop-2-oxy. Preferably R* is methoxy, amino- or guanidino-(C3_5)alkyloxy, guanidino(C3_5)alkyloxy, piρeridyl(C3_ 5)alkyloxy, nitro or fluoro, most preferably methoxy. R a is preferably hydrogen.
R3 preferably contains carboxy, cyano or 2-oxo-oxazolidinyl optionally substituted by R10.
Where R3 is substituted alkyl is it preferably substituted methyl. Examples of R3 include CO2H, CH2CO H, (CH2)2CO2H, (CH2)2CN, CONH2,
CH(OH)CH2CN, CH(OH)CH2CO2H, CH=CHCO2H or 2-oxo-oxazolidinyl. R3 is preferably in the 3-position. R3 is most preferably CH2CO2H or 2-oxo-oxazolidinyl. Preferably A is NH, NCH3, O, CH , CHOH, CH(NH2), C(Me)(OH) or CH(Me). Preferably B is CH2, CHOH or CO.
Preferably n is 0 or 1. More preferably: when A is NH, B is CO and n is 1 or 0; when A is O, B is CH2 and n is 1 or 0; when A is CH2 or CH2OH, B is CH2, and n is 1 or 0; when A is NCH3, CH(NH2), C(Me)(OH) or CH(Me), B is CH2 and n is 1; when A is CR6R7 and B CR8R9 and R6 and R8 together represent -O- and R7 and R9 are both hydrogen and n is 1.
AB(CH2)n is most preferably (CH2>3.
Suitable groups R4 include n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-dodecyl, methoxybutyl, phenylethyl, phenylpropyl or 3-phenyl-prop-2-en-yl optionally substituted on the phenyl ring, 3-benzoylpropyl, 4-benzoylbutyl, 3-pyridylmethyl, 3-(4- fluorobenzoyl)propyl, cyclohexylmethyl, cyclobutylmethyl, t- butoxycarbonylaminomethyl and phenoxyethyl.
Preferably R4 is (C5_ιo)alkyl, unsubstituted phenyl(C2-3)alkyl or unsubstituted phenyl(C3_4)alkenyl, more preferably hexyl, heptyl, 5-methylhexyl, 6-methyl heptyl, 3- phenyl-prop-2-en-yl or 3-phenylpropyl, most preferably n-heptyl.
Most preferably R^ is unbranched at the α and, where appropriate, β positions.
Halo or halogen includes fluoro, chloro, bromo and iodo.
The term heterocyclic ' as used herein includes aromatic and non-aromatic, single and fused, rings suitably containing up to four hetero-atoms in each ring selected from oxygen, nitrogen and sulphur, which rings may be unsubstituted or substituted by, for example, up to three groups selected from optionally substituted amino, halogen, (Cι_ 6>alkyl, (Cι_6)alkoxy, halo(Cι _6)alkyl, hydroxy, carboxy, carboxy salts, carboxy esters such as (Cι_6)alkoxycarbonyl, (Cι-6)alkoxycarbonyl(Cι _6)alkyl, aryl, and oxo groups. Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring. Compounds within the invention containing a heterocyclyl group may occur in two or more tautometric forms depending on the nature of the heterocyclyl group; all such tautomeric forms are included within the scope of the invention.
Where an amino group forms part of a single or fused non-aromatic heterocyclic ring as defined above suitable optional substituents in such substituted amino groups include (C\ _6)alkyl optionally substituted by hydroxy, (Cι_6)alkoxy, thiol, (C . 6)alkylthio, halo or trifluoromethyl, and amino-protecting groups such as acyl or (Cι _ 6)alkylsulphonyl groups.
The term lieteroaryr includes the aromatic heterocyclic groups referred to above. Examples of heteroaryl groups include pyridyl, triazolyl, tetrazolyl, indolyl, thienyl, isoimidazolyl, thiazolyl, fiιranyl,quinolinyl, imidazolidinyl and benzothienyl. When used herein the term 'aryl', includes phenyl and naphthyl, each optionally substituted with up to five, preferably up to three, groups selected from halogen, mercapto, (Cι _6)alkyl, phenyl, (Cι_g)alkoxy, hydroxy(Cι_6)alkyl, mercapto (Cι_6)alkyl, halo(Cι_6)alkyl, hydroxy, optionally substituted amino, nitro, carboxy, (Cj. 6)alkylcarbonyloxy, (Cι_6)alkoxycarbonyl, formyl, or (Cι_6)alkylcarbonyl groups.
The term 'acyl' includes (Cι_6)alkoxycarbonyl, formyl or (Ci -.^) alkylcarbonyl group.
Compounds of formula (I) wherein R3 is other than (Cι_6)alkoxycarbonyl; optionally substituted aminocarbonyl, CN or COOH, hereinafter 'compounds of formula (LA)' and pharmaceutically acceptable derivatives thereof are novel and as such form part of the invention.
The invention also provides a pharmaceutical composition comprising a compound of formula (IA), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier. Some of the compounds of this invention may be crystallised or recrystallised from solvents such as organic solvents. In such cases solvates may be formed. This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation. Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably from 10 to 59% of a compound of the formula (I) or salt thereof.
Pharmaceutically acceptable derivatives of the above-mentioned compounds of formula (I) include the free base form or their acid addition or quaternary ammonium salts, for example their salts with mineral acids e.g. hydrochloric, hydrobromic, sulphuric nitric or phosphoric acids, or organic acids, e.g. acetic, fumaric, succinic, maleic, citric, benzoic, p-toluenesulphonic, methanesulphonic, naphthalenesulphonic acid or tartaric acids. Compounds of formula (I) may also be prepared as the N-oxide. Compounds of formula (I) having a free carboxy group may also be prepared as an in vivo hydrolysable ester. The invention extends to all such derivatives.
Examples of suitable pharmaceutically acceptable in vivo hydrolysable ester- forming groups include those forming esters which break down readily in the human body to leave the parent acid or its salt. Suitable groups of this type include those of part formulae (i), (ii), (iii), (iv) and (v):
Ra
(I)
CH-O.CO.R
.Rα
-Rc-N<_ (II)
•CH,— OR' (III)
wherein Ra is hydrogen, (Cι_6) alkyl, (C3.7) cycloalkyl, methyl, or phenyl, R^ is (Cj.g) alkyl, (C g) alkoxy, phenyl, benzyl, (C3.7) cycloalkyl, (C3-.7) cycloalkyloxy, (Cι_6) alkyl (C3.7) cycloalkyl, 1-amino (C . ) alkyl, or l-(Cι_6 alkyl)amino (C\. ) alkyl; or Ra and RD together form a 1,2-phenylene group optionally substituted by one or two methoxy groups; Rc represents ( . ) alkylene optionally substituted with a methyl or ethyl group and R^ and Re independently represent (C\. ) alkyl; R^ represents (C . ) alkyl; RS represents hydrogen or phenyl optionally substituted by up to three groups selected from halogen, (C^) alkyl, or (C\. ) alkoxy; Q is oxygen or NH; R*1 is hydrogen or (C _£) alkyl; R1 is hydrogen, (C g) alkyl optionally substituted by halogen, (C2-6) alkenyl, (C . ) alkoxycarbonyl, aryl or heteroaryl; or R*1 and R1 together form (Cj.g) alkylene; R) represents hydrogen, (C\. ) alkyl or (C . ) alkoxycarbonyl; and R^ represents (C^.g) alkyl, (C\.^) alkoxy, (C\. ) alkoxy(Cι_6)alkoxy or aryl. Examples of suitable in vivo hydrolysable ester groups include, for example, acyloxy(Cι_6)alkyl groups such as acetoxymethyl, pivaloyloxymethyl, α-acetoxyethyl, α-pivaloyloxyethyl, l-(cyclohexylcarbonyloxy)prop-l-yl, and (l-aminoethyl)carbonyloxymethyl; (Cj.6)alkoxycarbonyloxy(Cι_6)alkyl groups, such as ethoxycarbonyloxymethyl, α-ethoxycarbonyloxyethyl and propoxycarbonyloxyethyl; di(Cι_6)a^^ylaπιino(Cι_6)alkyl especially di(Cι _4)alkylamino(Cι_4)alkyl groups such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl; 2-((Ci-6)alkoxycarbonyl)-2-(C2_6)alkenyl groups such as
2-(isobutoxycarbonyl)pent-2-enyl and 2-(ethoxycarbonyl)but-2-enyl; lactone groups such as phthalidyl and dimethoxyphthalidyl.
A further suitable pharmaceutically acceptable in vivo hydrolysable ester-forming group is that of the formula:
wherein R^ is hydrogen, C\. alkyl or phenyl.
R is preferably hydrogen.
Certain of the above-mentioned compounds of formula (I) may exist in the form of optical isomers, e.g. diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures. The invention includes all such forms, in particular the pure isomeric forms. For examples the invention includes compound in which an A-B group CH(OH)-CH2 is in either isomeric configuration, the R-isomer is preferred. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.
In a further aspect of the invention there is provided a process for preparing compounds of formula (IA), or a pharmaceutically acceptable derivative thereof, which process comprises:
(a) reacting a compound of formula (IN) with a compound of formula (V):
(IN) (V) wherein Z1, Z2, Z3, Z4 and Z5, m, n, R1, R2, R3 and R4 are as defined in formula (I), and X and Y may be the following combinations: (i) X is M and Y is CH2CO2Rx (ii) X is CO2R and Y is CH2CO2Rx (iii) one of X and Y is CH=SPh2 and the other is CHO (iv) X is CH3 and Y is CHO (v) X is CH3 and Y is CO2Rx (vi) X is CH2CO2Ry and Y is CO2Rx (vii) X is CH=PRZ 3 and Y is CHO (viii) X is CHO and Y is CH=PRZ 3 (ix) X is halogen and Y is CH=CH2
(x) one of X and Y is COW and the other is NHR 11 ' or NCO (xi) one of X and Y is (CH2)p- V and the other is (CH2)qNHR 11 ', (CH2)qOH, (CH )qSH or (CH2)qSCORx where p+q=l (xii) one of X and Y is CHO and the other is NHR 1 1 ' (xiii) one of X and Y is OH and the other is -CH=N2 in which V and W are leaving groups, Rx and Ry are (Cι_6)alkyl and Rz is aryl or (C\. 6)alkyl, or
(xiv) X is NCO, Y is OH or NH2 ;
(b) reacting a compound of formula (IN) with a compound of formula (Vb):
(IN) (Vb) wherein Z , Z2, Z3, Z4 and Z5, m, n, R1, R2, R3 and R4 are as defined in formula (I), X is CH2ΝHR11' and Y is CHO or COW or X is CH2OH and Y is -CH=N2;
(c) rearranging a compound of formula (II):
to give a compound of formula (III) which is a compound of formula (I) where Z^-Z^ are CH, n is 1 , A-B is COCH2 and R2 is H, or a compound of formula (VII) which is a compound of formula (I) where n is 1, A-B is CHOHCH2 or CH2CHOH and R2 is H; or
(d) photooxygenating a compound of formula (VI):
in which TT-T? are Z^-Z^ or groups convertible thereto, R^ , R* , R , R3' and R4' are R! 1, Rl, R2, R3 and R4 or groups convertible thereto, and thereafter optionally or as necessary converting R1 *', R1 ', R2', R3' and R4' to R1 1 R1, R2, R3 and R4, converting Z1 -Z5' to Z!-Z5, converting A-B to other A-B, interconverting R1 A R , R2, R3 and/or R4 and forming a pharmaceutically acceptable derivative thereof.
Process variants (a)(i) and (a)(ii), (c) in certain aspects and (d) initially produce compounds of formula (I) where A-B is COCH2. The products of variants (c) and (d) have n=l.
Process variant (a)(iii) and (c) in other aspects initially produces compounds of formula (I) wherein A-B is CH2CHOH or CHOHCH2.
Process variant (a)(iv) initially produces compounds of formula (I) wherein A-B is CH2CHOH. .
Process variants (a)(v) and (a)(vi), initially produce compounds of formula (I) wherein A-B is CH2CO. Process variants (a)(vii), (a)(viii) and (a)(ix) initially produce compounds where
A-B is CH=CH.
Process variant (a)(x) initially produces compounds of formula (I) wherein A-B is CONHRl l or NHRl lCO.
Process variant (a)(xi) initially produces compounds of formula (I) wherein one of A and B is CH2 and the other is NHR1 1 , O or S.
Process variant (a)(xii), initially produce compounds of formula (I) wherein A-B is CH2NHR11 or NHRl 1CH2.
Process variant (a)(xiii) initially produces compounds of formula (I) wherein A-B is OCH2 or CH O. Process variant (a)(xiv) initially produces compounds of formula (I) where A-B is NHC(O)NH or NHC(O)O.
Process variant (b) initially produces compounds of formula (I) wherein A is CH2 and B is NHR1 1 or O. In process variant (a)(i) M is preferably an alkali metal, more preferably Li. The reaction is conducted in an aprotic solvent preferably THF, ether or benzene at -78 to 25°C. An analogous route is described in G. Grethe et al (1972) Helv. Chimica.Acta., 55, 1044.
In process variant (a)(ii) the process is two step: firstly a condensation using a base, preferably sodium hydride or alkoxide, sodamide, alkyl lithium or lithium dialkylamide, preferably in an aprotic solvent e.g. ether, THF or benzene; secondly, hydrolysis using an inorganic acid, preferably HC1 in aqueous organic solvent at 0- 100°C. Analogous routes are described in DE330945, EP31753, EP53964 and H. Sargent, J. Am. Chem. Soc. 68, 2688-2692 (1946). In process variant (a)(iii) if a base is used it is preferably NaH, KH, an alkyl lithium e.g. BuLi, a metal alkoxide e.g. NaOEt, sodamide or lithium dialkylamide e.g.di- isopropylamide. An analogous method is described in US 3989691 and in Taylor et al. (1972) JACS 94, 6218)
In process variant (a)(iv) the reaction is carried out in the presence of a base, preferably organometallic or metal hydride e.g. NaH, lithium diisopropylamide or NaOEt, preferably in an aprotic solvent, preferably THF, ether or benzene at -78 to 25°C (analogous process in Gutswiller et al. (1978) JACS 100, 576).
In process variant (a)(v) the reaction is carried out in the presence of a base, preferably organometallic or metal hydride e.g. NaH, lithium diisopropylamide or NaOEt, preferably in an aprotic solvent, preferably THF, ether or benzene at -78 to 25°C. An analogous method is described in US 3772302.
In process variant (a)(vi) a similar Claisen methodology to that described for (a)(ii) is used, analogous to that described in Soszko et. al., Pr.Kom.Mat. Przyr.Poznan.Tow.Przyj.Nauk., (1962), 10, 15. In process variants (a)(vii) and (viii) if a base is used it is preferably NaH, KH, an alkyl lithium e.g. BuLi, a metal alkoxide e.g. NaOEt, sodamide or lithium dialkylamide e.g.di- isopropylamide. An analogous method is described in US 3989691 and M. Gates et. al. (1970) J. Amer.Chem.Soc, 92, 205, as well as Taylor et al. (1972) JACS 94, 6218. In process variant (a)(ix) the reaction is carried out using palladium catalysis. The palladium catalyst is preferably palladium acetate in the presence of trialkyl or triaryl phosphine and a trialkylamine e.g. triphenyl phosphine and tributylamine. An analogous method is described in S. Adam et. al. (1994) Tetrahedron, 50, 3327. In process variant (a)(x), or (b) where Y is COW,the reaction is a standard amide formation reaction:
1. Activation of a carboxylic acid (e.g., to an acid chloride, mixed anhydride, active ester, O-acyl-isourea or other species), and treatment with an amine (Ogliaruso, M. A.; Wolfe, J. F. in 77ιe Chemistry of Functional Groups (Ed. Patai, S.) Suppl. B: The Chemistry of Acid Derivatives, Pt. 1 (John Wiley and Sons, 1979), pp 442-8; Beckwith, A. L. J. in 77ze Chemistry of Functional Groups (Ed. Patai, S.) Suppl. B: The Chemistry of Amides (Ed. Zabriclcy, J.) (John Wiley and Sons, 1970), p 73 ff. The acid and amide are preferably reacted in the presence of an activating agent such as l-(dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (EDC) or 1-hydroxybenzotriazole (HOBT),
2. Aminolysis of esters (Suzuki, K.; Nagasawa, T. in Encyclopedia of Reagents for Organic Synthesis (Ed. Paquette, L. A.) (John Wiley and Sons, 1995), p 5188 and refs. cited therein.)
3. The specific methods of: a. in situ conversion of an acid into the amine component by a modified Curtius reaction procedure (Shioiri, T.; Murata, M.; Hamada, Y., Chem. Pharm. Bull 1987, 35, 2698) b. in situ conversion of the acid component into the acid chloride under neutral conditions (Villeneuve, G. B.; Chan, T. H., Tet. Lett. 1997, 38, 6489).
In process variant (b) a final reduction step provides the required amine. In process variant (a)(xi) where one of X and Y contains NHR1 ^ the leaving group V is halogen and the reaction is a standard amine formation reaction such as direct alkylation described in (Malpass, J. R., in Comprehensive Organic Chemistry, Vol. 2 (Ed. Sutherland, I. O.), p 4 ff.) or aromatic nucleophilic displacement reactions (see references cited in Comprehensive Organic Chemistry, Vol. 6, p 946-947 (reaction index); Smith, D. M. in Comprehensive Organic Chemistry, Vol. 4 (Ed. Sammes, P. G.) p 20 ff.). This is analogous to the methods described in GB 1177849.
In process variant (a)(xi) where one of X and Y contains OH or SH, this is preferably converted to an OM or SM group where M is an alkali metal by treatment of an alcohol, thiol or thioacetate with a base. The base is preferably inorganic such as NaH, lithium diisopropylamide or sodium, or, for SH, metal alkoxide such as sodium methoxide. The X/Y group containing the thioacetate SCORx is prepared by treatment of an alcohol or alkyl halide with thioacetic acid or a salt thereof under Mitsunobu conditions. The leaving group V is a halogen. The reaction may be carried out as described in Chapman et.al., J. Chem Soc, (1956),1563, Gilligan et. al., J. Med. Chem., (1992), 35, 4344, Aloup et. al., J. Med. Chem. (1987), 30, 24, Gilman et al., JΛ.C.S. (1949), 71, 3667 and Clinton et al., J.A.C.S. (1948), 70, 491, Barluenga et al., J. Org. Chem. (1987) 52, 5190. Alternatively where X is OH and Y is CH2V, V is a hydroxy group activated under Mitsunobu conditions (Fletcher et.al. J Chem Soc. (1995), 623).
In process variants (a)(xii) and (b) where Y is CHO the reaction is a standard reductive alkylation using, e.g., sodium triacetoxyborohydride (Gribble, G. W. in Encyclopedia of Reagents for Organic Synthesis (Ed. Paquette, L. A.) (John Wiley and Sons, 1995), p 4649).
In process variant (a)(xiii), or (b) where X is CH2OH and Y is -CH=N2, the reaction is as described in den Hertzog et. al., recl.Trav. Chim. Pays-Bas, (1950),69, 700. In process variant (a)(xiv) the reaction of the compounds of formulae (IV) and (V) is a standard urea or carbamate formation reaction conducted by methods well known to those skilled in the art (for example see March, J; Advanced Organic Chemistry, Edition 3 (John Wiley and Sons, 1985)). The process is preferably carried out in a polar, non-nucleophilic solvent such as N,N-dimethylformamide.
In process variant (c) the rearrangement may be effected by treatment with an acid, preferably an organic acid such as acetic acid and the reaction temperature is 80- 120°C. Alternatively the compound of formula (II) is quaternised by treatment with an alkylating agent and treated with base such as KOH to give, depending upon the stereochemistry of the OH and the nature of the quaternery salt and base, either the ketone of formula (HI) or an epoxide which can be opened to the alcohol of formula (VII by reduction (see EP0035821 ).
In process variant (d) the reaction is preferably carries out in an alcohol, preferably methanol under irradiation conditions which are known to generate singlet oxygen as described in M. Ihara et.al. (1988), J.Chem Soc Perkin Trans. 1, 1277.
Reduction of A or B CO to CHOH can be readily accomplished using reducing agents well known to those skilled in the art, e.g. sodium borohydride in aqueous ethanol or lithium aluminum hydride in ethereal solution.. This is analogous to methods described in EP 53964, US 384556 and J. Gutzwiller et. al. (1978) J.Amer.Chem.Soc, 100, 576.
The carbonyl group A or B may be reduced to CH2 by treatment with a reducing agent such as hydrazine in ethylene glycol at 130-160°C in the presence of potassium hydroxide.
Reaction of a carbonyl group A or B with an organometallic reagent yields a group where R6 or R8 is OH and R7 or R9 is alkyl.
A hydroxy group in A or B may be oxidised to a carbonyl group by oxidants well known to those skilled in the art , for example, manganese dioxide, pyridinium chlorochromate or pyridinium dichromate. An A-B group COCH2 may be converted to COCH-halogen, by treating the ketone or a derivative with a halogenating agent, reduced to CHOHCHC1 and then converted to the epoxide which may in turn be reduced to CH2CHOH.
Methods for conversion of CH=CH by reduction to CH2CH2 are well known to those skilled in the art, for example using hydrogenation over palladium on carbon as catalyst. Methods for conversion of CH=CH to give the A-B group as CHOHCH2 or CH2CHOH are well known to those skilled in the art for example by epoxidation and subsequenct reduction by metal hydrides, hydration, hydroboration or oxymercuration.
A hydroxyalkyl group A-B CH2CHOH or CHOHCH2 may be dehydrated to give the group CH=CH by treatment with an acid anhydride such as acetic anhydride.
An amide group CONHR1 1 ' or NHR1 ^ CO may be reduced to the amine using a reducing agent such as lithium aluminium hydride
A ketone group may be converted to an amide CONH via the oxime by a Beckmann rearrangement (Ogliaruso, M.A.; Wolfe, J. F., ibid, pp 450-451; Beckwith, A. L. I., ibid, pp 131 ff.)
A hydroxy group in A or B may be converted to azido by activation and displacement e.g. under Mitsunobu conditions using hydrazoic acid or by treatment with diphenylphosphorylazide and base, and the azido group in turn may be reduced to amino by hydrogenation. A sulphur group A or B may be converted to the sulphoxide S(O)x by oxidation with peracids or a wide range of oxidants known to those skilled in the art (see Advanced Organic Chemistry (Ed. March, J.) (John Wiley and Sons, 1985), p 1089 and refs. cited therein).
R1', R2', R3' and R4' are preferably R1, R2, R3 and R4. R1' is preferably methoxy. R2' is preferably hydrogen. R3' is preferably vinyl or contains a carboylate ester group. R4' is preferably H, R4 or a protecting group.
Conversions of R1 ', R2', R3' and R4' and interconversions of R1, R2, R3 and R4 are conventional. In compounds which contain an optionally substituted hydroxy group, suitable conventional hydroxy protecting groups which may be removed without disrupting the remainder of the molecule include acyl and alkylsilyl groups.
For example R1 ' methoxy is convertible to R1 ' hydroxy by treatment with lithium and diphenylphosphine (general method described in Ireland et. al. (1973) J.Amer.Chem.Soc.,7829) or HBr. Alkylation of the hydroxy group with a suitable alkyl derivative bearing a leaving group such as halide and a protected amino, piperidyl, amidino or guanidino group or group convertible thereto, yields, after conversion/deprotection, R Cμόalkoxy substituted by optionally N-substituted amino, piperidyl, guanidino or amidino. Examples of Z1 -Z^' are CRl a' where Rl a' is a group convertible to Rl a. R3' alkenyl is convertible to hydroxyalkyl by hydroboration using a suitable reagent such as 9-borabicyclo[3.3.1]nonane, epoxidation and reduction or oxymercuration. R3' 1 ,2-dihydroxy can be prepared from R3' alkenyl using osmium tetroxide or other reagents well known to those skilled in the art (see Advanced Organic Chemistry (Ed. March, J.) (John Wiley and Sons, 1985), p 732-737 and refs. cited therein) or epoxidation followed by hydrolysis (see Advanced Organic Chemistry (Ed. March, J.) (John Wiley and Sons, 1985), p 332,333 and refs. cited therein). Opening an epoxide R3' group with cyanide anion yields a CH(OH)-CH2CN group.
Opening an epoxide-containing R3' group with azide anion yields an azide derivative which can be reduced to the amine. Conversion of the amine to a carbamate is followed by ring closure with base to give the 2-oxo-oxazolidinyl containing R3 group. Substituted 2-oxo-oxazolidinyl containing R3 groups may be prepared from the corresponding aldehyde by conventional reaction with a glycine anion equivalent, followed by cyclisation of the resulting amino alcohol (M Grauert et al, Ann Chem (1985) 1817, Rozenberg et al, Angew Chem Int Ed Engl (1994) 33(1) 91). The resulting 2-oxo- oxazolidinyl group contains a carboxy group which can be converted to other R1^ groups by standard procedures.
Carboxy groups within R3 may be prepared by Jones' oxidation of the corresponding alcohols CH2OH using chromium acid and sulphuric acid in water/methanol (E.R.H. Jones et al, J.C.S. 1946,39). Other oxidising agents may be used for this transformation such as sodium periodate catalysed by ruthenium trichloride (G.F.Tutwiler et al, J.Med.Chem., 1987, 30(6), 1094), chromium trioxide-pyridine (G. Just et al, Synth. Commun. 1979, 9(7), 613), potassium permanganate (D.E.Reedich et al, J. Org. Chem.,1985,50(19),3535, and pyridinium chlorochromate (D. Askin et al, Tetrahedron Letters, 1988, 29(3), 277.
The carboxy group may alternatively be formed in a two stage process, with an initial oxidation of the alcohol to the corresponding aldehyde using for instance dimethyl sulphoxide activated with oxalyl chloride (N.Cohen etal, J. Am. Chem. Soc, 1983, 105, 3661) or dicyclohexylcarbodiimide (R.M.Wengler, Angew. Chim. Int. Ed. Eng., 1985, 24(2), 77), or oxidation with tetrapropylammonium perruthenate (Ley et al, J. Chem.Soc. Chem Commun., 1987, 1625). The aldehyde may then be separately oxidised to the corresponding acid using oxidising agents such as silver (H) oxide (R.Grigg et al, J. Chem. Soc. Perkinl,1983, 1929), potassium permanganate (A.Zurcher, Helv. Chim. Acta., 1987, 70 (7), 1937), sodium periodate catalysed by ruthenium trichloride (T.Sakata et al, Bull. Chem. Soc. Jpn., 1988, 61(6), 2025), pyridinium chlorochromate (R.S.Reddy et al, Synth. Commun., 1988, 18(51), 545) or chromium trioxide (R.M.Coates et al, J. Am. Chem. Soc, 1982, 104, 2198).
An R3 CO2H group may also be prepared from oxidative cleavage of the corresponding diol, CH(OH)CH2OH, using sodium periodate catalysed by ruthenium trichloride with an acetontrile-carbontetrachloride- water solvent system (V.S.Martin et al, Tetrahedron Letters, 1988, 29(22), 2701).
R3 groups containing a cyano or carboxy group may also be prepared by conversion of an alcohol to a suitable leaving group such as the corresponding tosylate by reaction with para-toluenesulphonyl chloride (M.R.Bell, J. Med. Chem., 1970, 13, 389), or the iodide using triphenylphosphine, iodine, and imidazole (G. Lange, Synth. Commun., 1990, 20, 1473). The second stage is the displacement of the leaving group with cyanide anion (LA.Paquette et al, J. Org. Chem.,1979, 44 (25), 4603; P.A.Grieco et al, J. Org. Chem., 1988, 53 (16), 3658). Finally acidic hydrolysis of the nitrile group gives the desired acids (H.Rosemeyer et al, Heterocycles, 1985, 23 (10), 2669). The hydrolysis may also be carried out with base e.g. potassium hydroxide (H.Rapoport, J. Org. Chem., 1958, 23, 248) or enzymatically (T. Beard et al, Tetrahedron Asymmetry, 1993, 4 (6), 1085). Other functional groups in R3 may be obtained by conventional conversions of carboxy or cyano groups. Tetrazoles are conveniently prepared by reaction of sodium azide with the cyano group (e.g. F. Thomas et al, Bioorg. Med. Chem. Lett., 1996, 6 (6), 631; K.Kubo et al, J. Med. Chem., 1993, 36,2182) or by reaction of azidotri-n-butyl stannane with the cyano group followed by acidic hydrolysis ( P.L.Ornstein, J. Org. Chem., 1994, 59, 7682 and J. Med. Chem, 1996, 39 (11), 2219). The 3-hydroxy-3-cyclobutene-l,2-dion-4-yl group (e.g. R.M.Soll, Bioorg. Med.
Chem. Lett., 1993, 3 (4), 757 and W. A. Kinney, J. Med. Chem., 1992, 35 (25), 4720) can be prepared by the following sequence:- (1) a compound where R3 is (CH2)nCHO (n = 0,1,2) is treated with triethylamine, carbontetrabromide triphenylphosphine to give initially (CH2)nCH=CHBr; (2) dehydrobromination of this intermediate to give the corresponding bromoethyne derivative (CH2)nC≡CBr (for this 2 stage sequence see D. Grandjean et al, Tetrahedron Letters, 1994, 35 (21), 3529); (3) palladium-catalysed coupling of the bromoethyne with 4-(l-methylethoxy)-3-(tri-n-butylstannyl)cyclobut-3- ene-l,2-dione (Liebeskind et al, J. Org. Chem., 1990, 55, 5359); (4) reduction of the ethyne moity to -CH2CH2- under standard conditions of hydrogen and palladium on charcol catalysis(see Howard et al, Tetrahedron, 1980, 36, 171); and finally (4) acidic hydrolysis of the methylethoxyester to generate the corresponding 3-hydroxy-3- cyclobutene-l,2-dione group R.M.Soll, Bioorg. Med. Chem. Lett., 1993, 3 (4), 757). The tetrazol-5-ylaminocarbonyl group may be prepared from the corresponding carboxylic acid and 2-aminotetrazole by dehydration with standard peptide coupling agents such as l,l'-carbonyldiimidazole (P. L. Ornstein et al, J. Med Chem, 1996, 39 (11), 2232). The alkyl- and alkenyl-sulphonylcarboxamides are similarly prepared from the corresponding carboxylic acid and the alkyl- or alkenyl-sulphonamide by dehydration with standard peptide coupling agents such as 1 , 1 -carbonyldiimidazole (P. L. Ornstein et al, J.Med.Chem., 1996, 39 (11), 2232).
The hydroxamic acid groups are prepared from the corresponding acids by standard amide coupling reactions eg N. R. Patel et al, Tetrahedron, 1987, 43 (22), 5375 2,4-Thiazolidinedione groups may prepared from the aldehydes by condensation with 2,4-thiazolidinedione and subsequent removal of the olefinic double bond by hydrogenation.
The preparation of 5-oxo-l,2,4-oxadiazoles from nitriles is decribed by Y.Kohara et al, Bioorg. Med. Chem. Lett, 1995, 5(17), 1903. l,2,4-Triazol-5-yl groups may be prepared from the corresponding nitrile by reaction with an alcohol under acid conditions followed by reaction with hydrazine and then an R ^-substituted activated carboxylic acid (see JB Polya in 'Comprehensive Heterocyclic Chemistry' Edition 1 p762, Ed AR Katritzky and CW Rees, Pergamon Press, Oxford 1984 and J.J. Ares et al, J. Heterocyclic Chem., 1991, 28(5), 1197).
Other substituents on R3 alkyl or alkenyl may be interconverted by conventional methods, for example hydroxy may be derivatised by esterification, acylation or etherification. Hydroxy groups may be converted to halogen, thiol, alkylthio, azido, alkylcarbonyl, amino, aminocarbonyl, oxo, alkylsulphonyl, alkenylsulphonyl or aminosulphonyl by conversion to a leaving group and substitution by the required group or oxidation as appropriate or reaction with an activated acid, isocyanate or alkoxyisocyanate. Primary and secondary hydroxy groups can be oxidised to an aldehyde or ketone respectively and alkyated with a suitable agent such as an organometallic reagent to give a secondary or tertiary alcohol as appropriate. NH is converted to NR4 by conventional means such as alkylation with an alkyl halide in the presence of base, acylation/reduction or reductive alkylation with an aldehyde.
It will be appreciated that under certain circumstances interconvertions may interfere, for example, A or B hydroxy groups and the piperidine NH will require protection e.g. as a carboxy- or silyl-ester group for hydroxy and as an acyl derivative for piperidine nitrogen, during conversion of R ', R2 , R3' or R4', or during the coupling of the compounds of formulae (IV) and (V). Examples containing a trα«5-3,4-substituted piperidine ring may be prepared from the trans-3-vinyl-4-substituted piperidine prepared from the corresponding 3-vinyl-4- .y- isomer by the method of G. Engler et al. Helv. Chim. Acta 68, 789-800 (1985); also described in Patent Application EP 0031753 (Pharmindustrie). The method involves heating a 3-vinyl-4-alkyl-piperidine derivative of formula
(prepared as an intermediate in the process of the invention) in dilute acid, preferably hydrochloric acid at pH 3.5, with 0.3-1.0 mol equivalents of formaldehyde. The main product of the reaction is the trans-isomer, which may be separated from the small quantity of cis isomer present, by conventional silica gel chromatography. It is convenient to convert the mixture of cis- and tr ns-piperidines (R4' = H) to the tertiary amines of formula (I) by alkylation with an alkyl halide (preferably an iodide) in DMF in the presence of anhydrous potassium carbonate, prior to silica gel chromatography. Compounds of formula (II) include quinine and derivatives thereof. Compounds of formula (VI) are known compounds or may be prepared analogously, see for example Ihara et al JCS Perkin 1 1988, 1277-1281. Compounds of formulae (IV), (V) and (Vb) are known compounds, (see for example Smith et al, J. Amer. Chem. Soc, 1946, 68, 1301) or prepared analogously, see for example the references cited above for reaction variant (a).
An isocyanate of formula (IV) may be prepared conventionally. A 4-amino derivative such as 4-amino-quinoline, and phosgene, or phosgene equivalent (eg triphosgene) provide the isocyanate or it may be prepared more conveniently from a 4-carboxylic acid by a 'one-pot' Curtius Reaction with diphenyl phosphoryl azide (DPP A) [see T. Shiori et al. Chem. Pharm. Bull. 35, 2698-2704 (1987)].
The 4-carboxy derivatives are commercially available or may be prepared by conventional procedures for preparation of carboxy heteroaromatics well known to those skilled in the art. For example, quinazolines may be prepared by standard routes as described by T.A. Williamson in Heterocyclic Compounds, 6, 324 (1957) Ed. R.C. Elderfield. Pyridazines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 3, Ed A.J. Boulton and A. McKillop and napthyridines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 2, Ed A.J. Boulton and A. McKillop.
The 4-amino derivatives are commercially available or may be prepared by conventional procedures from a corresponding 4-chloro derivative by treatment with ammonia (O.G. Backeberg et. al., J. Chem Soc, 381, 1942.) or propylamine hydrochloride (R. Radinov et. al., Synthesis, 886, 1986).
A 4-chloroquinoline is prepared from the corresponding quinolin-4-one by reaction with phosphorus oxychloride (POCl3) or phosphorus pentachloride, PC15 A 4-chloroquinazoline is prepared from the corresponding quinazolin-4-one by reaction with phosphorus oxychloride (POCl3) or phosphorus pentachloride, PC15. A quinazolinone and quinazolines may be prepared by standard routes as described by T.A. Williamson in Heterocyclic Compounds, 6, 324 (1957) Ed. R.C. Elderfield. Pyridazines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 3, Ed A.J. Boulton and A. McKillop and napthyridines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 2, Ed A.J. Boulton and A. McKillop.
4-Hydroxy-l,5-naphthyridines can be prepared from 3-aminopyridine derivatives by reaction with diethyl ethoxymethylene malonate to produce the 4-hydroxy-3- carboxylic acid ester derivative with subsequent hydrolysis to the acid, followed by thermal decarboxylation in quinoline (as for example described for 4-Hydroxy- [l,5]naphthyridine-3-carboxylic acid, Joe T. Adams et al, JΛmer.Chem.Soc, 1946, 68, 1317). A 4-hydroxy-[l,5]naphthyridine can be converted to the 4-chloro derivative by heating in phosphorus oxychloride. A 4-amino 1 ,5-naphthyridine can be obtained from the 4-chloro derivative by reaction with n-propylamine in pyridine. Similarly, 6-methoxy-l,5-naphthyridine derivatives can be prepared from 3-amino-6- methoxypyridine.
4-Methyl-l,5-naphthyridines can be prepared by methods well known to those skilled in the art (for example see H. Rapoport and A. D. Batcho, Journal of Organic Chemistry, 1963, 1753-1759). For example, nitrobenzene can be heated with oleum over a period of hours then water and a 3-aminopyridine added with heating. Slow addition of methyl vinyl ketone with heating produces the desired 4-methyl-l,5-naphthyridine.
1,5-Naphthyridines may be prepared by other methods well known to those skilled in the art (for examples see P.A. Lowe in "Comprehensive Heterocyclic Chemistry" Volume 2, p581-627, Ed A.R. Katritzky and CW. Rees, Pergamon Press, Oxford, 1984).
The 4-hydroxy and 4-amino-cinnolines may be prepared following methods well known to those skilled in the art [see A.R. Osborn and K. Schofield, J. Chem. Soc. 2100 (1955)]. For example, a 2-aminoacetopheneone is diazotised with sodium nitrite and acid to produce the 4- hydroxycinnoline with conversion to chloro and amino derivatives as described for 1 ,5- naphthyridines. A 3-methyl substituent may be introduced by reaction of a 4-chlorocmnohne with lithium diisopropylamide at -75°C followed by alkylation with methyl iodide [see A. Turck et al. Tetrahedron, 47, 13045 ( 1995)].
For compounds of formula (V) where Y is NHR1 1 suitable amines may be prepared from the corresponding acid or alcohol (Y is CO2H or CH2OH). In a first instance, an N-protected piperidine containing an acid bearing substituent, can undergo a Curtius rearrangement and the intermediate isocyanate can be converted to a carbamate by reaction with an alcohol. Conversion to the amine may be achieved by standard methods well known to those skilled in the art used for amine protecting group removal. For example, an acid substituted N-protectedpiperidine can undergo a Curtius rearrangement e.g. on treatment with diphenylphosphoryl azide and heating, and the intermediate isocyanate reacts in the presence of 2-trimethylsilylethanol to give the trimethylsilylethylcarbamate (T .Capson & C.D.Poulter. Tetrahedron Letters.1984. 25. 3515).
This undergoes cleavage on treatment with tetrabutylammonium fluoride to give the 4-amine substituted N-protectedpφeridine. Alternatively, an acid group (CH2)n-lCO2H may be converted to (CH2)nNHRj j by reaction with an activating agent such as isobutyl chloro formate followed by an amine R 1 1 NH2 and the resulting amide reduced with a reducing agent such as
LiAlH4.
In a second instance, an N-protected piperidine containing an alcohol bearing substituent undergoes a Mitsunobu reaction (for example as reviewed in Mitsunobu, Synthesis, (1981), 1), for example with succinimide in the presence of diethyl azodicarboxylate and triphenylphosphine to give the phthalimidoethylpiperidine.
Removal of the phthaloyl group, for example by treatment with methylhydrazine, gives the amine of formula (V).
Conversions of R1 ', R2', R3 and R4 may be carried out on the intermediates of formulae (II), (IV), (V), (Vb) and (VI) prior to their reaction to produce compounds of formula (I) in the same way as described above for conversions after their reaction.
Where a trarc,y-substituted compound of formula (I) is required, a trans-substituted piperidine moiety of formula (V) may be prepared from the corresponding cis isomer of formula (V) having an R vinyl group in the 3-position with a substituent that can subsequently be converted to the required group (CH2)nY, for example CH2CO2R
(where R is an alkyl group eg methyl or ethyl), by heating in formaldehyde.
The pharmaceutical compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans. The antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics. The composition may be formulated for administration by any route, such as oral, topical or parenteral. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions. The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams. The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents. Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.
For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
The compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.
No toxicological effects are indicated when a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof is administered in the above-mentioned dosage range.
The compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a β-lactamase inhibitor may be employed.
Compounds of formula (I) are active against a wide range of organisms including both Gram-negative and Gram-positive organisms.
The following examples illustrate the preparation of certain compounds of formula (I) and the activity of certain compounds of formula (I) against various bacterial organisms.
EXAMPLES
Example 1 [3R, 4R]-l-HeptyI-3-(l-(R or S)-hydroxy-2-cyanoethyl)-4-[3-(6- methoxyquinolin-4-yI)propyl]piperidine a) [3R,4R]-3-Ethenyl-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine. A solution of quinine (497g) in acetic acid (460 ml) and water (3.8 1) was heated to reflux for 2 days. The mixture was basified with 40% aqeuous sodium hydroxide solution and extracted (2x) with dichloromethane. The organic extracts were washed with brine, dried (Na2SO4) and evaporated affording the title compound as a brown oil (497g,100%). El MH+ 325, C2oH24N2O requires 324.
b) [3R,4R]-3-Ethenyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine.
A solution of Example la(231.5g, 0.71 mol) in ethylene glycol (1.01) was treated with hydrazine hydrate (50g, 1.0 mol) over 0.3 h. The mixture was warmed to 120°C for 1.5h. The mixture was then cooled to 10°C and potassium hydroxide (92.7g) was added and the mixture extracted with dichloromethane (2x). The dichloromethane extracts were washed with brine, dried (Na2SO4), and evaporated affording the title compound as a brown oil (217g, 100%). El MH+ 311 C20H26N2O requires 310.
c) [3R,4R]-l-Benzyloxycarbonyl-3-ethenyl-4-[3-(6-methoxyquinolin-4- yl)propyl]piperidine.
A solution of crude Example lb (496g, 1.5mol) in tetrahydrofuran (4.5 1) and water 3.3 1) was treated with solid potassium carbonate (219.6g, 1.6mol) and then a solution of benzyl chloroformate (258g, 1.5mol) in tetrahydrofuran (0.4 1) was added over 1 h. The mixture was stirred at room temperature for 15 h then sodium chloride (500g) and ethyl acetate (2.5 1) were added. After stirring for 0.25 h the organic phase was separated and the aqueous phase re-extracted with ethyl acetate. The combined ethyl acetate extracts were dried (Na2Sθ4) and evaporated affording as brown oil. This was chromatographed (in two portions) on 2.5kg silica Biotage cartridges eluting first with dichloromethene then 5% ethyl acetate in hexane to give the title compound a clear oil that crystallised on standing (450.5g, 67%). El MH+ 445 C28H32N2O3 requires 444.
d) [3R,4R]- 1 -Benzyloxycarbonyl-3-( 1 -(R,S)-2-dihydroxyethyl)-4-[3-(6-methoxyquinolin- 4-yl)propyl]piperidine A solution of Example lc (215g, 0.48mol) in acetone (4.2 1) and water 0.53 1) under argon at 0°C was treated with osmium tetroxide (2.5g) in t-butanol (300 ml) dropwise over 0.5 h. A solution of N-methylmorpholine-N-oxide (77.6g, 0.66 mol) was in water (0.7 1) was then added dropwise over 1 h. The mixture was stirred for 16 h at room temperature. A solution of sodium metabisulphite (65.5g, 0.34 mol) in water (0.5 1) was added. After 4 h the mixture was filtered through celite (CAUTION - to remove Osmium metal), washing with acetone. The filtrate was concentrated by evaporation then solid sodium bicarbonate (50g) and ethyl acetate (2.5 1) were added. The organic extract was washed with brine dried (Na2SO4), and evaporated, giving a yellow oil (235g). This was purified by chromatography on a 2.5kg silica bioptage cartridge eluting with 1 : 1 ethyl acetate:hexane , neat ethyl acetate, then up to 5% methanol in ethyl acetate, affording the title compound as a yellow oil (179.9g, 78%). El MH+ 478 C28H34N2O5 requires 477.
e) I3R, 4R]- 1 -Benzyloxycarbonyl-3-(2-(R, S)-oxiranyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.
This was prepared by a modification of a related procedure by S. Takano et al. Synthesis, 1983, 116.
The above diol Example Id (9.0g, 18.8 mmol) was dissolved in toluene (150ml) then triphenylphosphine (7.4g, 28.2 mmol) and diethylazodicarboxylate (4.9g, 28.2 mmol) were added. The mixture was heated to reflux under argon for 2.5 days. Evaporation and chromatography on silica eluting with a gradient of ethyl acetate/hexane (70/30) to neat ethyl acetate afforded a white solid (20.0g). Analysis of this material showed it to contain ca. 9g of the title compound, the balance being triphenylphosphine oxide.
E.I MH+ 461 C28H32N2O4 requires 460
f) [3R, 4R]-l-Benzyloxycarbonyl-3-(l-(R,S)-hydroxy-2-cyanoethyl)-4-[3-(6- methoxyquinolin-4-yl) propyl] piperidine. The above semi-purified epoxide Example le (10.9g, equivalent to approximately
5.0g, 10.9 mmol) was dissolved in tetrahydrofuran (160 ml) and treated with lithium cyanide in N,N-dimethylformamide (0.5 M; 100ml, 50mmol). The mixture was heated to reflux under argon for 9 hours, and evaporated to dryness. The residue was partitioned between ethyl acetate and water. The organic extract was dried and evaporated affording the crude product as a brown solid ( 1 lg).
E.I. MH+ 488, C29H33N3O4 requires 487. g) [3R, 4R]-3-( 1 -(R, S)-hydroxy-2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.
The above crude cyanohydrin Example If (approximately 10.9 mmol) was dissolved in ethanol (130ml) and hydrogenated over 10% palladium on charcol (5.6g) for 21 hours. Filtration and evaporation afforded a brown oil. Chromotagraphy on silica eluting with a mixture of aqueous ammonia: methanol: dichloromethane (1.5: 15:30) afforded the pure product as an inseparable 2: 1 mixture of diastereomers as a clear oil (1.28g, 33% over two stages from epoxidele)
E.I. MH+ 354, C21H27N3O2 requires 353.
h) Title compounds
The above piperidine Example lg (1.26g, 3.6 mmol) was dissolved in N,N- dimethylformamide (20ml), then treated with potassium carbonate (0.6g, 4.3 mmol) and heptyl iodide (0.65 ml, 0.9g, 3.9mmol). After 3.5 h the reaction mixture was evaporated and the residue partitioned between ethyl acetate and dilute brine. The organic extract was dried and evaporated giving a brown oil. Chromatography on silica eluting with aqueous ammonia-ethanol-dichloromethane (1.5-15-350) affording the individual diastereomers as yellow oil (combined yield 0.56g, 34%). E.I. MH+ 452, C28H41N3O2 requires 451.
Example 2. [3R, 4R]-l-Heptyl-3-(2-(R or S)-oxo-oxazoIidin-5-yl)-4-[3-(6- methoxyquinolin-4-yl) propyl] piperidine a) [3R, 4R]-l-Benzyloxycarbonyl-3-(l-(R,S)-hydroxy-2-azidoethyl)-4-[3-(6- methoxyquinolin-4-yl) propyl] piperidine. This was prepared by the same procedure as for Example If, except that sodium azide was used instead of lithium cyanide and 0.5 equivalents of ammonium chloride were included in the reaction mixture.
E.I. MH+ 504, C28H33N5O4 requires 503.
b) [3R, 4R]-l-Benzyloxycarbonyl-3-(l-(R,S)-hydroxy-2-aminoethyl)-4-[3-(6- methoxyquinolin-4-yl) propyl] piperidine.
The crude product Example 2a (2.58g, contaminated with Ph3P=O) was dissolved in ethanol (70ml) and hydrogenated over 10% palladium on charcoal (0.9g) for 0.5h.
This facilitated the selective reduction of the azide functionality in the presence of the N- benzyloxycarbonyl protecting group. Filtration and evaporation afforded the crude product as a pale yellow solid (2.3g).
E.I. MH+ 478, C28H35N3O4 requires 477. c) [3R, 4R]-l-Benzyloxycarbonyl-3-(l-(R,S)-hydroxy-2- benzyloxycarbonylaminoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine
The above crude product (Example 2b) was dissolved in ethyl acetate and vigorously stirred with an equal volume of saturated aqueous sodium bicarbonate solution. Benzyl chloroformate (1.3 equivalents) was added and the mixture stirred under argon for 5 h. The phases were separated and the ethyl acetate extract dried and evaporated. The crude material was purified by chromatography eluting with an ethyl acetate/hexane gradient. E.I. MH+ 612, C36H41N3O6 requires 611
d) [3R, 4R]-l-Benzyloxycarbonyl-3-(2-(R,S)-oxo-oxazolidin-5-yl)-4-[3-(6- methoxyquinolin-4-yl) propyl] piperidine.
The above alcohol (0.16g, 0.26mmol) was dissolved in a mixture of water:methanol:tetrahydrofuran (0.75ml: 1.5ml:3ml) containing potassium hydroxide (0.32g). The mixture was stirred for 3h at room temperature then diluted with water (10ml) and extracted with ethyl acetate (30ml). The organic extract was dried (Na2 SO4 ) and evaporated. The crude material was purified by chromatography on silica eluting with a 0→2% ethanol in ethyl acetate gradient affording the product as a yellow oil (O.lg, 80%).
E.I. MH+ 504, C29H33N3O5 requires 503.
e) [3R, 4R]-3-(2-(R,S)-oxo-oxazolidin-5-yl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine Hydrogenation of the above compounds (Example Id) according to the method for Example lg with the variation that the reaction time was 4 h, gave the title compounds as an oil.
E.I. MH+ 370, C21H27N3O3 requires 369
f) Title compound
The title compounds were prepared by N-heptylation of the above compound (Example 2e) according to the method of Example lh followed by chromatography on silica eluting with aqueous ammonia:ethanol:chloroform (1.5:15:400) to give the individual diastereomers (65 mg and 24mg) as oils in a combined yield of 34%. E.I. MH+ 468, C28H41N3O3 requires 467. Example 3. [3R, 4R]-l-Heptyl-3-(2-cyanoethyl)-4-[3-(6-methoxyquinoIin-4-yl) propyl] piperidine. a) [3R,4R]-l-Benzyloxycarbonyl-3-(2-hydroxyethyl)-4-[3-(6-methoxyquinolin-4- yl)propyl]piperidine. The olefin Example lc (10.00 g, 22.5 mmol) was dissolved in tetrahydrofuran
(300 ml) and treated with with a solution of 9-borabicyclo(3.3.1.)nonane in hexane (0.5M, 135 ml, 67.6 mmol) and heated to reflux for 24h under argon. The cooled reaction mixture was treated with ethanol (70 ml) and 2M aqueous sodium hydroxide solution (70 ml), then 27.5 w/v aqueous hydrogen peroxide solution (45 ml) was added over 20 minutes.After lh ethyl acetate and water were added, and the organic extract dried and evaporated. The crude product was purified by chromatography on silica gel eluting with an ethyl acetate gradient affording the titile product as a yellow oil (6.3g, 60%). E.I. MH+ 463, C28H34N2O4 requires 462.
b) (3R, 4R)-3-(2-hydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine. This was prepared in approximately quantitative yield from the above N- benzyloxycarbonyl piperidine (Example 3a) by hydrogenation according to the procedure for Example lg, with the variation that the reaction time was 3h.
E.I. MH+ 329, C20H28N2O2 requires 328.
c) (3R, 4R)- 1 -t-butyloxycarbonyl-3-(2-hydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.
Example 3b was dissolved in dichloromethane-N,N-dimethylformamide and treated with triethylamine (1.2 eq),di-t-butylcarbonic anhydride (1.1 equivalents ) and N,N-dimethylaminopyridine (catalytic quantity). After stirring overnight the mixture was evaporated and purified by chromatography on silica eluting with a gradient of ethyl acetate/hexane, giving the product as an oil ( 3.8g, 34%)
E.I MH+ 429, 329 (loss ofCO2C4H9), C25H36N2O4 requires 428.
d) (3R, 4R)-1- tert-butyloxycarbonyl-3-[2-(4-methylphenyl)sulfonyloxyethyl]-4-[3-
(6-methoxyquinolin-4-yl) propyl] piperidine.
Example 3c (2.2g, 5.1 mmol) was dissolved in dichloromethane (50ml), then triethylamine ( 0.85ml, 0.62g, 6.1 mmol), N,N- dimethylaminopyridine (catalytic) and 4-methylphenylsulfonyl chloride (l.lg, 5.6 mmol) were added. After 20h the mixture was diluted with more dichloromethane and washed with water. The organic extract was dried (Na2SO4) and evaporated. Chromatography on silica eluting with ethyl acetate: hexane (1: 1) afforded the product as a yellow oil ( 1.8g, 61%).
E.I. MH+ 583, C32H42N2O6S requires 582.
e) (3R, 4R)-1- t-butoxycarbonyl-3-(2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.
Example 3d (1.8g, 31mmol) was dissolved in N,N-dimethylformamide (15ml) and treated with sodium cyanide ( 0.3g, 6.2 mmol). The mixture was stirred at room temperature for 16 h then at 40° for lh. The mixture was evaporated to dryness and the residue was partitioned between ethyl acetate and water. The organic extract was dried (MgSO4) and evaporated to give the product as an oil, (67%). E.I. MH+ 438, C26H35N3O3 requires 437.
f) (3R, 4R)-3-(2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine. Example 3e (0.9g) was treated with 1:1 trifluoroacetic acid:dichloromethane (25 ml)at 0 C. After lh the reaction mixture was evaporated and the residue partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution.. The organic extract was dried and evaporated to give the title compound as an oil in approximately quantitative yield. E.I MH+ 338, C21H27N2O2 requires 337.
g) Title compound
The title compound was prepared from Example 3f by heptylation using the procedure of Example lh, giving the purified product as an oil (0.55g, 62%)
E.I. MH+ 436, C28H14N3O requires 435.
Example 4. [3R, 4R]-l-Heptyl-3-(3-carboxyethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine. Hydrolysis of the corresponding cyanoethyl compound (Example 3g)
(0.35g,0.8mmol) with concentrated hydrochloric acid and dioxane ( 9ml of each) at reflux for 1 lh followed by evaporation and chromatography on silica (eluting with 1.5:15:50 aqueous ammonia:methanol:chloroform) afforded the title compound (0.23g, 55%) as an oil. E.I. MH+, 455, C28H42N2O2 requires 454. Example 5. [3R, 4R]-l-Heptyl-3-carboxy-4-[3-(6-methoxyquinoIin-4-yl) propyl] piperidine. a) (3R, 4R)-3-(l-(R,S)-2-Dihydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine The title compounds (4.7g) were prepared in approximately quantitative yield by hydrogenation of Example Id according to the same procedure as for Example lg, with the variation the reaction time was 3h. E.I. MH+ 345, C2θH28N2°3 requires 344.
b) (3R, 4R)-3-( 1 -(R,S)-2-Dihydroxyethyl)- 1 -heptyl-4-[3-(6-methoxyquinolin-4-yl) propyl]piperidine
The title compounds were prepared in approximately 60% yield by alkylation at room temperature with heptyl iodide (1.1 equivalents) in N,N-dimethylformamide as solvent and potassium carbonate (1.2 equivalents) as base, following an analogous procedure to Example lh.
E.I. MH+ 443, C27H42N2O3 requires 442.
c) Title compounds
A solution of the above diol (Example 5b) (0.4g) in acetone (10ml) was treated at 0°C with Jones reagent (-50 drops). After 2h the reaction mixture was neutralised with saturated aqueous sodium bicarbonate solution and extracted (3x) with ethyl acetate. The combined organic extracts were dried and evaporated. Chromatography on silica eluting with aqueous ammonia-ethanol-chloroform (1.5:15:300) afforded the title compounds as a yellow oil (32 mg, 8%). E.I. MH+ 427, C26H38N2O3 requires 426.
Example 6. [3R, 4R]-l-Heptyl-3-(carboxymethyl)-4-[3-(6-methoxyquinolin-4-yI) propyl] piperidine. a) [3R,4R]-3-Ethenyl- 1 -heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine This was prepared in 66% yield from (Example lb) by heptylation according to the procedure for Example lh. E.I MH+ 409, C27H40N2O requires 408.
b) (3R, 4R)-l-heptyl-3-(2-hydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine
This was prepared from Example 6a in 40% yield by the same hydroboration oxidation procedure as for Example 3a. E.I MH+ 427, C27H42N2O2 requires 426.
c) (3R, 4R)-l-heptyl-3-(2-carboxymethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine This was prepared in 15% yield from Example 6b using the same oxidation procedure as for Example 5c E.I. M+H 441, C27H40N2O3 requires 440.
Example 7 [3R, 4R]-l-HeptyI-3-(l-(R or S)-hydroxy-2-carboxyethyI)-4-[3-(6- methoxy quinolin-4-yl)propyl]piperidine
A solution of Example 1(60 mg, 0.13 mmol) in concentrated hydrochloric acid:dioxane (6 ml:3 ml) was heated to reflux for 4h. The mixture was neutralised with saturated aqueous sodium bicarbonate solution and extracted (3X) with ethyl acetate. The combined organic extracts were dried and evaporated and the crude product chromatographed on silica eluting with aqueous ammonia:methanol:chloroform (1.5:15:50) giving the title compounds as a colourless oil, (0.019g, 30%). E.I. MH+ 471, C28H42N2O3 requires 470.
Example 8 [3R, 4R]-l-Heptyl-3-(2-(E-)-carboxyethenyl)-4-[3-(6-methoxyquinolin-4- yl)propyl]piperidine
A solution of Example 1(48 mg, 0.11 mmol) in concentrated hydrochloric acid:dioxane (5 ml:3 ml) was heated to reflux for 24h. The mixture was neutralised with saturated aqueous sodium bicarbonate solution and extracted (3X) with ethyl acetate. The combined organic extracts were dried and evaporated and the crude product chromatographed on silica eluting with aqueous ammonia:methano:chloroform (1.5:15:50) giving the title compound as a colourless oil, (0.015g, 31%). E.I. MH+ 453, C28H40N2O2 requires 452.
Example 9. N-(cis-3-(R/S)-Ethoxycarbonyl-l-heptyl-4-(S/R)-piperidyl)-N'-(6- methoxyquinolin-4-yl)urea oxalate a) 4-Benzylamino- 1 -tert-butoxycarbonyl-3-ethoxycarbonyl- 1 ,2,5 ,6-tetrahydroρyridine A solution of l-tert-butoxycarbonyl-3-ethoxycarbonylpiperidin-4-one (prepared from 3-ethoxycarbonylpiperidin-4-one and di-tert-butyl-dicarbonate in dichloromethane and triethylamine) (25g) and benzylamine (10.85g) in toluene was heated under reflux in a Dean and Stark apparatus for 18 hours and then evaporated to dryness to give an oil. b) cis- 4-(S/R)-Benzylamino- l-tert-butoxycarbonyl-3-(R S)-ethoxycarbonylpiperidine
The enamine (9a) (25g) in ethanol (300ml) was hydrogenated over platinum oxide (1.5g) for 4 days, filtered, and evaporated to dryness. It was chromatographed on silica gel (ethyl acetate-hexane) to afford the title compound as an oil. MS (+ve ion electrospray) m z 363 (MH+).
c) cis-4-(S/R)-Amino-l-tert-butoxycarbonyl-3-(R/S)-ethoxycarbonylpiperidine The amine (9b) (4g) in ethanol (80ml) containing acetic acid (0.73g) was hydrogenated at 50psi (Parr reaction vessel) over 10% palladium-carbon (lg) for 18 hours, filtered and evaporated to dryness to afford the acetate salt of the title compound as a white solid (3g).
MS (+ve ion electrospray) m/z 273 (MH+).
It was converted to the oily free base by extraction using dichloromethane-sodium carbonate and drying over sodium sulfate.
d) N-(cis- 1 -tert-Butoxycarbonyl-3-(R S)-ethoxycarbonyl-4-(S/R)-piperidyl)-N'-(6- methoxyquinolin-4-yl)urea
A suspension of 6-methoxyquinoline-4-carboxylic acid (0.98g) in dry toluene (50ml) was treated with triethylamine (1.95g) followed by diphenylphosphoryl azide (1.39g) and the mixture was stirred at room temperature for 8 hours. The resultant solution was treated with the amine (9c) and then heated under reflux for 4 hours and evaporated to dryness. The product was chromatographed on silica gel (ethyl acetate- hexane) to afford the title compound (1.98g) as a foam. MS (+ve ion electrospray) m/z 473 (MH+).
e) N-(cis-3-(R S)-Ethoxycarbonyl-4-(S/R)-piperidyl)-N-(6-methoxyquinolin-4-yl)urea
The urea (9d) (l.Og) was treated with dichloromethane (30ml) and trifluoroacetic acid (20ml) at room temperature for 3 hours and evaporated to dryness. It was basified with sodium carbonate solution and evaporated to dryness. The solid was extracted three times with ethanol-chloroform (1:9) and evaporated to dryness to afford a foam (0.75g). MS (+ve ion electrospray) m/z 373 (MH+).
f) Title compound
The amine (9e) (0.75g) in dry ethanol (15ml) was treated with heptaldehyde (0.636g) and sodium triacetoxyborohydride (0.459g) for 1 hour at room temperature. Sodium bicarbonate solution was added and the mixture was extracted with dichloromethane, dried over sodium sulfate, and evaporated to afford an oil. Chromatography on silica gel (ethyl acetate-hexane) gave the title compound (0.68g) as an oil.
MS (+ve ion electrospray) m/z 471 (MH+).
The free base in dichloromethane was treated with 1 molar equivalent of oxalic acid in ether and the resulting solid was collected, triturated with ether, to afford the oxalate salt as a white solid.
Example 10. N-(cis-3-(R/S)-Ethoxycarbonyl-l-heptyl-4-(S/R)-piperidyl)-N'-(6- methoxy-[l,5]-naphthyridin-4-yl)urea oxalate a) 4-Hydroxy-6-methoxy-[l,5]naphthyridine-3-carboxylic acid ethyl ester
3-Amino-6-methoxypyridine (12.41 g) and diethyl ethoxymethylene malonate (20.2 ml) in Dowtherm A (400 ml) were heated at reflux, under argon for 1 hour. The cooled reaction mixture was poured into pentane (1 litre). The precipitated solid was collected by filtration, washed with pentane and dried to afforded a solid (24.78 g, crude).
b) 4-Hydroxy-6-methoxy-[l,5]naphthyridine-3-carboxylic acid
The ester (10a) (0.642g) in 10% aqueous sodium hydroxide (115 ml) was heated at reflux for 1.5 hours. The reaction mixture was cooled then acidified with glacial acetic acid. The precipitated solid was collected by filtration, washed with water and dried in vacuo to afford a beige solid (0.542g).
MS (+ve ion electrospray) m/z 221 (MH+).
c) 4-Chloro-6-methoxy-[ 1 ,5]naphthyridine
The acid (10b) (6.82 g) was heated in quinoline (20ml) at reflux for 2 hours, the mixture was cooled and poured into ether (200ml) and the orange solid was filtered and washed with ether (5 x 200ml). A sample (3.87g) of the dried solid was treated with phosphorus oxychloride (30ml) at room temp for 3 hours, the solvent was removed in vacuo and the residue quenched with crushed ice (200g). The mixture was basified with ammonia solution and filtered. The solid was washed with dichloromethane (10 x 100ml), which was evaporated and chromatographed on silica gel (dichloromethane as eluent) to give a yellow solid (3.0g). MS (+ve ion electrospray) m z 195, 197 (MH+).
d) 4-Amino-6-methoxy-[ 1 ,5]naphthyridine A solution of the chloro compound (10c) (2.0g) in pyridine (30ml) was treated with n-propylamine hydrochloride (6.0g) and the mixture heated at reflux for 16 hours. The reaction mixture was cooled and partitioned between water and ethyl acetate. The aqueous phase was washed with ethyl acetate, the combined organics dried (Na SO4) and the solvent removed under reduced pressure. Purification by chromatography on silica gel (5-10% methanol in dichloromethane) afforded a yellow solid (l.Og). Η NMR (CDCI3) 6: 4.05 (3H, s), 5.36 (2H, bs), 6.71 (IH, d, J=5 Hz), 7.08 (IH, d, J=9Hz), 8.10 (IH, d, J=9Hz), 8.40 (IH, d, J=5Hz). MS (+ve ion electrospray) m z: 176 (MH+).
e) N-(cis-l-tert-Butoxycarbonyl-3-(R/S)-ethoxycarbonyl-4-(S/R)-piperidyl)-N'-(6- methoxy-[ 1 ,5]-naphthyridin-4-yl)urea To a solution of amine (lOd) (0.5g) in chloroform (4ml) was added 1,1 - carbonyldiimidazole (0.76g) and dimethylaminopyridine (0.38g) and the solution was stirred at room temperature for 3.5 hours and evaporated to dryness. The product was heated at 100°C in dry DMF (7ml) containing the amine (9c) (0.85g), for 3 hours.
Aqueous sodium carbonate was added and the mixture was extracted with dichloromethane, dried over sodium sulfate, and evaporated to afford a foam.
Chromatography on silica gel (ethyl acetate-hexane) gave an oil (0.928g).
MS (+ve ion electrospray) m/z 474 (MH+).
f) N-(cis-3-(R/S)-Ethoxycarbonyl-4-(S/R)-piperidyl)-N'-(6-methoxy-[ 1 ,5]-naphthyridine- 4-yl)urea
The urea (lOe) (0.92g) was treated with dichloromethane (20ml) and trifluoroacetic acid (30ml) at room temperature for 3 hours and evaporated to dryness. It was basified with sodium carbonate solution and evaporated to dryness. The solid was extracted three times with warm ethanol-chloroform (1:9) and evaporated to dryness to afford a foam (0.80g).
MS (+ve ion electrospray) m/z 374 (MH+).
g) Title compound
The amine (lOf) (0.80g) in dry ethanol (20ml) was treated with heptaldehyde (0.26g) and sodium triacetoxyborohydride (0.82g) for 1 hour at room temperature.
Sodium bicarbonate solution was added and the mixture was extracted with dichloromethane, dried over sodium sulfate, and evaporated to afford an oil.
Chromatography on silica gel (ethyl acetate-hexane) gave the title compound (0.72g) as an oil. MS (+ve ion electrospray) m/z 472 (MH+). The free base in dichloromethane was treated with 1 molar equivalent of oxalic acid in ether and the resulting solid was collected, triturated with ether, to afford the oxalate salt as a white solid.
Example 11. N-(cis-3-(R/S)-Aminocarbonyl-l-heptyI-4-(S/R)-piperidyI)-N'-(6- methoxy-[l,5]-naphthyridin-4-yl)urea oxalate
The ester Example 10 (0.105g) in methanol (2ml) was heated with ammonia (3ml) and sodium cyanide (2mg) at 50°C (sealed bomb) for 3 days and evaporated to dryness. Chromatography on silica gel (ethyl acetate then methanol-dichloromethane) gave the title compound (0.024g), as the free base. MS (+ve ion electrospray) m/z 443 (MH+).
The free base in dichloromethane-ether was converted to the oxalate salt in the normal manner, affording a white solid.
Example 12. [3R, 4R]-l-Heptyl-4-[3-(R/S)-hydroxy-3-(6-methoxyquinolin-4- yl)propyl]-3-(2-(R or S)-oxo-oxazolidin-5-yl)-piperidine a) 9-O-Acetyl-(R/S)-10,l 1-epoxyquinine
A solution of Example 13b (57g, 140 mmol) in toluene (1 1) was treated with triphenyl phosphine (114g, 440 mmol) and diethylazodicarboxylate (80 ml, 510 mmol). The mixture was heated to reflux for 8h, the cooled and chromatographed eluting with methanol in dichloromethane to give the product as an oil (12g, 22%). Η NMR (CDC13) δ: 4.00 (3H, s), 6.50 (IH, m), 7.20-7.50 (3H, m), 8.03 (IH, d), 8.72 (IH, d). El MH+ 383 C22H26 2O4 requires 382.
b) 9-O-Acetyl-(R/S)-l 1 -azido- 10-hydroxy- 10,11-dihydoquinine
A solution of Example 12a (12g, 31.4 mmol) in N,N-dimethylformamide (100 ml) was treated with sodium azide (11.7g) and ammonium chloride (lg) and heated at 140° C for 7h. The mixture was evaporated and the residue partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic extract was dried and evaporated. The residue was chromatographed on silica eluting with methanol in dichloromethan affording the title compound as an orange foam (2.03g, 15%). Η NMR (CDC13) δ: 3.95 (3H, s), 6.50 (IH, m), 7.30-7.50 (3H, m), 8.00 (IH, d), 8.70 (IH, d). El MH+ 426 C22H27N5O4 requires 425
c) 9-O- Acetyl- 11 -amino- 10-hydroxy- 10,11 -dihydroquinine
Azide 12b (2.03 g, 4.8 mmol) in ethanol (30 ml) was hydrogenated over 10% palladium on charcoal for 2 hours. The mixture was filtered through celite and evaporated. Chromatography on silica gel eluting with 5-20% methanol in dichloromethane containing 0.5-2% ammonia gave an orange oil (0.87g,46%). Η NMR (CDC13) δ: 3.96 (3H,s), 6.50 (lH,d), 7.32-7.48 (3H,m), 8.02 (IH, d), 8.74 (lH,d), E.I. MH+ 400, C22H29N3O requires 399.
d) 5-(R/S)-{2-S-[R-acetoxy-(6-methoxyquinolin-4-yl)methyl]-5-R- quinuclidinyl } oxazolidin-2-one
A solution of amine 12c (0.65 g, 1.63 mmol), in dichloromethane (25 ml) was treated with triethylamine (0.56 ml, 4.0 mmol) and triphosgene (0.20 g, 0.67 mmol). After being stirred for 2 hours, further triphosgene (0.05 g, 0.16 mmol) was added and stirring continued for 1 hour. The mixture was diluted with dichloromethane and washed with sodium carbonate solution, dried and evaporated. Chromatography on silica gel eluting with 2-5% methanol in dichloromethane gave an off-white foam (0.54g, 66%), 1H NMR (CDCI3) δ: 3.96 (3H,s), 4.45(lH,m), 5.43 (lH,s), 6.47 (lH,d), 7.30-7.45 (3H,m), 8.02 (lH,d), 8.74 (lH,d). E.I. MH+ 426, C23H27N3O5 requires 425.
e) (3R,4R)-3-(2-Oxo-oxazolidin-5-yl)-4-[3-oxo-3-(6-methoxyquinolin-4- yl)propyl]piperidine
A solution of 12(d) (0.266 g, 0.63 mmol) in water/acetic acid (3 ml/0.3 ml) was heated to reflux for 2 days. The mixture was basified with 40% sodium hydroxide solution and extracted with ethyl acetate. The organic extracts were dried and evaporated to give the title compound as a yellow oil (105 mg),
1H NMR (CDC13) δ: 3.94 (3H,s), 4.85(lH,m), 5.10 (lH,bs), 7.40 (lH,dd), 7.70 (IH, d),
7.85 (IH, d), 8.05 (lH,d), 8.90 (lH,d), E.I. MH+ 384 C21H25N3O4 requires 383.
f) (3R,4R)-l-Heptyl-3-(2-oxo-oxazolidin-5-yl)-4-[3-oxo-3-(6-methoxyquinolin-4- yl)propyl]piperidine
A solution of Example 12e(105 mg) in N,N-dimethylformamide (3 ml) was treated with potassium carbonate (0.14g) and heptyl iodide (0.2 ml). After 2h the reaction mixture was diluted with ethyl acetate and washed with sodium carbonate solution, brine, dried and evaporated. Chromatography on silica eluting with methanol in dichloromethane gave the title compound as a clear oil (70 mg, 23% over 2 stages), 1H NMR (CDC13) δ: 0.85 (3H, t), 1.20-1.45 (10H, m), 3.94 (3H,s), 4.85(lH,m), 5.65 (lH,bs), 7.40 (lH,dd), 7.75 (IH, d), 7.90 (IH, d), 8.10 (lH,d), 8.90 (lH,d), E.I. MH+ 482 C28H39N3O4 requires 481.
g) Title compounds A solution of Example 12f (42 mg, 0.09 mmol) in 2-propanol (5 ml) wastreated with sodium borohydride (20 mg). After 2h the mixture was diluted with water and extracted with dichloromethane. The organic extract was dried and evaporated. Chromatography on silica eluting with methanol in dichloromethan afforded the title compounds as a clear oil (30 mg, 71%),
1H NMR (CDC13) δ: 0.85 (3H, t), 1.20-1.45 (10H, m), 3.95 (3H,s), 4.85(lH,m), 5.90 (lH,m), 5.90 (IH, s), 7.25 (lH,dd), 7.32 (IH, d), 7.55 (IH, dd), 8.00 (lH,d), 8.70 (lH,m), E.I. MH+ 484 C28H41N3O4 requires 483.
Example 13. [3R, 4R]-l-Heptyl-3-cyanomethyl-4-[3-(R/S)-hydroxy-3-(6- methoxyquinolin-4-yl)propyI]piperidine a) O-Acetylquinine
A solution of quinine (97.2g , 300 mmol) in pyridine (300 ml) was treated with acetic anhydride (31 ml, 34g, 333mmol). After 4h the mixture was evaporated to dryness, azeotroping with water then toluene, affording the product an an oil which was used without further purification. El MH+ 367, C22H26N2O3 requires 366
b) 9-O-Acetyl-10,l l-dihydro-(R,S)10,l 1-dihydroxyquinine A solution of Example 13a in acetone-water (400 ml-150 ml) was treated with osmium tetroxide (2g) in tert-butanol (50 ml). A solution of N-methylmorpholine N- oxide (49. Ig, 420 mmol) was added. After 2 days more osmium tetroxide (lg) was added. After a further day sodium metabisulphite (30g) in water (100 ml) was added. After 2h the mixture was filtered and evaporated. The residue was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic extract was dried and chromatographed to give the diols as a white foam (109g, 91% over two steps). El MH+ 401, C22H28 2O5 requires 400
c) 9-O-Acetyl-10-al-l 1-norquinine A solution of Example 13b (1.8g, 4.4 mmol) in pH7 phosphate buffer (30 ml) was treated at 0° C with a slurry of sodium periodate (1.9g, 8.8 mmol) in water (10 ml). After 0.5h, the mixture was extracted three times with chloroform. The chloroform extract was dried and evaporated to give the title compound as a white foam (l.lg, 65%). 1H NMR (CDC13) δ: 3.95 (3H, s), 6.45 (IH, d), 7.35 (IH, m), 7.40 (IH, m), 8.05 (IH, d), 8.75 (IH, d), 9.75 (lH,s). El MH+ 367, C21H24N2O4 requires 368
d) 10-Cyano- 10,11 -dihydro- 11 -norquinine To a stirred suspension of potassium t-butoxide (6.28 g) in 1,2-dimethoxyethane (23 ml) kept below -30°C was added dropwise a solution of tosylmethyl isocyanide (5.62 g) in 1,2-dimethoxyethane (23 ml). After stirring for 20 minutes, a solution of Example 13c (lOg) in 1,2-dimethoxyethane (32 ml) and THF (30 ml) was slowly added to the reaction mixture at -50 to -60 °C. After 50 minutes methanol (40ml) was added to the cold solution which was heated at reflux for 15 minutes. The solvent was removed under reduced pressure and saturated sodium bicarbonate solution added. The mixture was extracted with dichloromethane, washed with brine, dried over anhydrous magnesium sulphate, filtered and the solvent removed under reduced pressure. Chromatogrphy on silica gel eluting with 5% methanol in dichloromethane gave a yellow foam (3.58g, 39 %).
Η NMR (CDC13) δ: 8.70 (d,lH), 8.00 (d,lH), 7.54 (d, IH), 7.34 (d,lH) 7.19 (d, IH) 5.62 (s,lH), 3.88 (s,3H) 3.45-3.6 (m,lH), 3.15-3.25 (m,lH), 3.00-3.15 (m,lH), 2.55-3.25 (m, IH), 2.38-2.50 (m, IH), 2.18-2.25 (m, 2H), 2.10-1.80 (m, 4H), 1.35-1.6 (m, 2H). EI MH+ 338 C20H23N3O2 requires 337.
e) [3R,4R]-3-Cyanomethyl-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine
A solution of Example 13d (3.58 g) in glacial acetic acid (4 ml) and water (40 ml) was heated at reflux under a flow of argon for 36 hours. The reaction mixture was taken to pH12 with sodium hydroxide solution. The mixture was extracted into ethyl acetate, dried over anyhydrous magnesium sulphate, filtered and the solvent removed under reduced pressure. Chromatography on silica gel eluting with 5 to 10 % methanol in dichloromethane gave the compound as an oil (0.830 g, 23%).
Η NMR (CDCI3) δ: 8.89 (d, IH), 8.07 (d, IH), 7.85 (d,lH), 7.61 (d,lH), 7.41 (d, IH), 3.95 (s,3H), 3.20-3.01 (m,4 H), 2.83-2.58 (m,3 H), 2.43-2.34 (m,lH), 2.00-2.18 (m,lH),
1.85-1.70 (m,3H), 1.65-1.50 (m,lH), 1.45-1.25 (m,lH).
El MH+ 338 C20H23N3O2 requires 337.
f) [3R,4R]-l-Heptyl-3-cyanomethyl-4-[3-oxo-3-(6-methoxyquinolin-4- yl)propyl]piperidine
Amine 13e (0.830g) was heptylated according to the method for example lh to give the compound as an oil (0.856g, 80%).
Η NMR (CDC13) δ: 8.89 (d,lH), 8.07 (d,lH), 7.85 (d,lH), 7.61 (d,lH), 7.41 (d, IH), 3.96 (s,3H), 3.15-2.96 (m,3H), 2.88-2.70 (m,2H), 2.45-1.90 (m,6H), 1.80-1.20 (m, 15H), 0.89 (t, 3H)
El MH+ 436 C27H37N3O2 requires 435.
g) Title compound A solution of ketone 13f (0.738g) in isopropanol (10 ml) was treated at 0°C with sodium borohydride (0.064g). The mixture allowed to warm to room temperature. After
3 hours, water (20 ml) was added and the mixture extracted with ethyl acetate. The combined organic layers were dried over anyhdrous magnesium sulphate, filtered and the solvet removed under reduced pressure. Chromatography on silica gel eluting with 1 to 5 % methanol in dichloromethane gave the title compound as a yellow oil (0.595 g, 80 %). Η NMR (CDC13) δ: 8.75 (d,lH), 8.05 (d,lH), 7.50 (d,lH), 7.37 (d,lH), 7.25 (d, IH), 5.40 (m,lH), 3.94 (s,3H), 3.05-2.55 (m,3H), 2.45-2.15 (m,3H), 2,10-1.75 (m,5H), 1.75- 1.10 (m,15H), 0.88 (t,3H). El MH+ 438 C27H39N3O2 requires 437.
Example 14. [3R, 4R]-l-Heptyl-3-cyanomethyl-4-(2-(R)-hydroxy-3-(6- methoxyquinolin-4-yl)propyl]piperidine a) [3R,4R]- 1 -Heptyl-3-cyanomethyl-4-[2(R),3(R)-oxiranyl-3-(6-methoxyquinolin-4- yl)propyl]piperidine A solution of 13d (3.2 g) in toluene (30 ml) and N,N-dimethylformamide (3ml) was heated at 80°C with heptyl bromide( 1.65ml) overnight under a stream of argon. Starting material was still present so heptyl iodide (0.8 ml) was added and the mixture heated at 80°C for 2 hours. The solvent was removed under reduced pressure and the residue was dissolved in t-butanol (40ml) and THF (10 ml). Potassium t-butoxide (1M in THF, 11ml) was added and the mixture heated at reflux under a stream of argon for 1 hour. The mixture was allowed to cool to room temperature, silica added and the solvent removed under reduced pressure. Chromatography on silica gel (dry loaded) eluting with 1 to 5 % methanol in dichloromethane gave the compound as a brown oil (1.72 g, 42%). 1H NMR (CDC13) δ: 8.75 (d,lH), 8.07 (d,lH), 7.43 (d,lH), 7.27 (m,2H), 4.18 (s,lH), 3.95 (s,lH), 3.05-2.65 (m,4H), 2.40-1.15 (m,23H), 0.90 (t,3H) El MH+ 436 C27H37N3O2 requires 435.
b) Title compound
A solution of oxirane 14a (1.32 g) in ethanol (30 ml), was treated withl0% palladium on charcoal (0.85 g) and the mixture hydrogenated at atmospheric pressure for
4 hours. The mixture was filtered through a small plug of celite and the solvent removed under reduced pressure. Chromatography on silica gel eluting with 2% methanol in dichloromethane gave the target compound as a brown oil (0.462 g, 35 %).
1H NMR (CDC13) δ: 8.37 (d,lH), 7.84 (d,lH), 7.28 (m,2H), 7.15 (d,lH), 4.24 (m,lH), 3.95 (s,3H), 3.20-3.30 (m,lH), 3.10-2.60 (m,5H), 2.45-1.10 (m,21H), 0.86 (t,3H). El MIT 438 C27H39N3O2 requires 437. The following compound Examples were prepared following the procedures described in the synthetic methodology section and previous preparative Examples:
Example 15. N-(cis-3-(R/S)-Carboxy-l-heptyl-4-(S/R)-piperidyl)-N'-(6- methoxyquinolin-4-yI)urea tris-trifluoroacetate
MS (+ve ion electrospray) m/z 443 (MH+).
Example 16. cis-3-(R S)-Ethoxycarbonyl-l-heptyl-4-(S/R)-(6-methoxyquinoIin-4- yI)aminocarbonyloxypiperidine MS (+ve ion electrospray) m/z 472 (MH+).
Example 17. cis-3-(R S)-Carboxy-l-heptyl-4-(S/R)-(6-methoxyquinolin-4- yl)aminocarbonyloxypiperidine
MS (+ve ion electrospray) m/z 444 (MH+).
The following compounds were prepared following the procedures described in the synthetic methodology section and previous preparative Examples
TABLE 1
Biological Activity
The MIC (μg/ml) of test compounds against various organisms was determined: S. aureus Oxford, S. aureus WCUH29, S. aureus Carter 37, E. faecalis I, M. catarrhalis Ravasio, S. pneumoniae R6. Examples 1 to 8, 12 to 14, 18 to 25, 33 and 36 have an MIC of less than or equal to 1 μg/ml against one or more of the above range of gram positive and gram negative bacteria.
Examples 11, 17, 26 to 32, 34 and 35 showed an MIC of less than or equal to 16μg/ml against one or more of the above range of gram positive and gram negative bacteria.
Examples 9, 10, 15 and 16 showed an MIC of less than or equal to 64μg/ml against one or more of the above range of gram positive and gram negative bacteria.

Claims

Claims
1. A method of treatment of bacterial infections in mammals, which method comprises the administration to a mammal in need of such treatment of an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof:
(I) wherein:
one of Z1, Z2, Z3, Z4 and Z5 is N or CRla and the remainder are CH;
R1 is selected from hydroxy; (C\. ) alkoxy optionally substituted by (Cι_6)alkoxy, amino, piperidyl, guanidino or amidino optionally N-substituted by one or two (C\_ ό^ky1 ' acy! or (Cι_6)alkylsulphonyl groups, NH2CO, hydroxy, thiol, (Cι_6)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C\_ 6)alkylsulphonyloxy; (Cι_6)alkoxy-substituted (Cι_6)alkyl; halogen; (Cι_6)alkyl; (C\_ 6)alkylthio; trifluoromethyl; nitro; azido; acyl; acyloxy; acylthio; (C 6)alkylsulphonyl; (Cι_6)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (Cι_6)alkyl, acyl or (C _
6)alkylsulphonyl groups, or when one of Z , Z2, 7?, Z4 and 7? is N, R1 may instead be hydrogen;
Rla is selected from hydrogen and the groups listed above for R1;
R3 is in the 2- or 3-position and is: carboxy; (Cι_6)alkoxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (Cι_6)alkyl, hydroxy(Cι_6)alkyl, aminocarbonyl(Cι_6)alkyl, (C2- g)alkenyl, (Cι_6)alkylsulphonyl, trifluoromethylsulphonyl, (Cμg)alkenylsulphonyl, (C\. 6)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (C2_6)alkenyloxycarbonyl or (C2- 6)alkenylcarbonyl and optionally further substituted by (Cι_6)alkyl, hydroxy(Cι_6)alkyl, aminocarbonyl(Cι_6)alkyl or (C2-6)alkenyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R1^; 3-hydroxy-3-cyclobutene-l,2-dione-4-yl; 2,4- thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; l,2,4-triazol-5-yl optionally substituted by R1^; or 5-oxo-l,2,4-oxadiazol-3-yl; or
R3 is in the 2- or 3-position and is (Cι_4)alkyl or ethenyl substituted with any of the groups listed above for R3 and 0 to 2 groups R12 independently selected from: thiol; halogen; (Cι _6)alkylthio; trifluoromethyl; azido; (Cι_6)alkoxycarbonyl;
(Cι_6)alkylcarbonyl; (C2-6)alkenyloxycarbonyl; (C2-6)alkenylcarbonyl; hydroxy optionally substituted by (Cι _6)alkyl, (C2- )alkenyl, (Cι_6)alkoxycarbonyl, (Cγ. 6)alkylcarbonyl, (C2-6) lkenyloxycarbonyl, (C2-6)a kenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (Cι_6)alkyl, (C2-6)al enyl, (C . 6)alkylcarbonyl or (C2-6) lkenylcarbonyl; amino optionally mono- or disubstituted by (Cι_6)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (C2-6)alkenyloxycarbonyl, (C2- 6)alkenylcarbonyl, (Cι_6)alkyl, (C2-6)alkenyl, (Cι_6)alkylsulphonyl, (C2. 6)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (Cι_6)alkyl or (C2-6)alkenyl; aminocarbonyl wherein the amino group is optionally substituted by (Cι_6)alkyl, hydroxy(C 6)alkyl, aminocarbonyl(Cι_6)alkyl, (C2-
6)alkenyl, (Cι_6)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (C2-6)alkenyloxycarbonyl or (C2. 6)alkenylcarbonyl and optionally further substituted by (Cι_6)alkyl, hydroxy(C 6)alkyl, aminocarbonyl(Cι_6)alkyl or (C2-6)a kenyl; oxo; (Cι_6)alkylsulphonyl; (C2. 6)alkenylsulphonyl; or (Cι_6)aminosulphonyl wherein the amino group is optionally substituted by (C ι_6)alkyl or (C2_6)alkenyl; provided that when R3 is disubstituted with hydroxy or amino and carboxy containing substituents these may optionally together form a cyclic ester or amide linkage, respectively; and provided that R3 is other than (Cj^alkyl or ethenyl substituted by (C\_ 6)a koxycarbonyl or aminocarbonyl optionally substituted by (Cι_6)alkyl, (C2-6) lkenyl, (Cι_6)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (C2-6)alkenyloxycarbonyl or (C2. g)alkenylcarbonyl and optionally further substituted by (Cι_6)alkyl, hydroxy(Cι_6)alkyl, aminocarbonyl(Cι_6)alkyl or (C2-6) lkenyl and 0 to 2 groups R12;
wherein R1^ is selected from (Cι_4)alkyl; (C2-4)alkenyl; aryl; a group R12 as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C2_6) lkenyl, (Cι_6)alkylsulphonyl, trifluoromethylsulphonyl, (Cι_6)alkenylsulphonyl, (Cι_(j)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (C2- 6)alkenyloxycarbonyl or (C2-6)a kenylcarbonyl and optionally further substituted by (Cι_ 6)alkyl or (C2-6)alkenyl; cyano; or tetrazolyl;
R4 is a group -CH2-R^ in which R^ is selected from: (C3.12)alkyl; hydroxy(C3.ι2)alkyl; (C1.12)alkoxy(C3.ι2)alkyl; (Ci . 12)alkanoyloxy(C3_i2)alkyl; (C3_6)cycloalkyl(C3_i2)alkyl; hydroxy-, (C i2)a o y- or (C 1 - 12) lkanoyloxy-(C3_6)cycloalkyl(C3_ \ 2)alky 1 ; cyano(C3_ 2)alkyl ; (C2- 12)alkenyl ; (C2-i2)a kynyl; tetrahydrofuryl; mono- or di-(Cι_i2)^ ylamino(C3_i2)al y acylamino(C3_i2)a yl; (Cι_i2)alkyl- or acyl-aminocarbonyl(C3_i2)alkyl; mono- or di- (Cl-12)alkylamino(hydroxy) (C3_i 2)alkyl; optionally substituted phenyl(Cι_2)alkyl, phenoxy(Cι_2)alkyl or phenyl(hydroxy)(Cι_2)a kyl; optionally substituted diphenyl(Cι_ 2)alkyl; optionally substituted phenyl(C2-3)alkenyl; optionally substituted benzoyl or benzoylmethyl; optionally substituted heteroaryl(Cι_2)alkyl;and optionally substituted heteroaroyl or heteroaroylmethyl;
n is 0, 1 or 2;
either A-B is NHC(O)NH or NHC(O)O, or
A is NR11, O, S(O)x or CR6R7 and B is NR11, O, S(O)x or CR8R9 where x is 0, 1 or 2 and wherein: each of R > and R7 R8 and R9 is independently selected from: H; thiol; (Cι_6)alkylthio; halo; trifluoromethyl; azido; (Cι_6)alkyl; (C2-6)alkenyl; (Cι_6)alkoxycarbonyl; (C\. 6)a kylcarbonyl; (C2-6) lkenyloxycarbonyl; (C2-6)alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R3; (Cj.
6)alkylsulphonyl; (C2-6)alkenylsulphonyl; or (Cμ6)aminosulphonyl wherein the amino group is optionally substituted by (Cι_6)alkyl or (Cι_6)alkenyl; or R^ and R8 together represent a bond and R7 and R9 are as above defined; or R6 and R& together represent -O- and R7 and R9 are both hydrogen; or R and R7 or R8 and R9 together represent oxo; and each R1 is independently H, trifluoromethyl, (Cι_6)alkyl, (Cι_6)alkenyl, (C\„ g)alkoxycarbonyl, (Cι_6)alkylcarbonyl, aminocarbonyl wherein the amino group is optionally substituted by (Cι_6)alkoxycarbonyl, (Cι_6)alkylcarbonyl, (C{_ 6)alkenyloxycarbonyl, (C2-6) lkenylcarbonyl, (Cj.gjalkyl or (Cι_6)alkenyl and optionally further substituted by (Cι_6)alkyl or (Cι_6)alkenyl;
provided that A and B cannot both be selected from NR1 !, O and S(O)x and when one of A and B is CO the other is not CO, O or S(O)x.
2. A compound of formula (IA) or a pharmaceutically acceptable derivative thereof which is a compound of formula (I) as defined in claim 1 wherein R3 is other than (C\_ 6)alkoxycarbonyl; optionally substituted aminocarbonyl, CN or COOH.
3. A compound according to claim 2 wherein 7? is CH or N and 7λ-7^ are each CH.
4. A compound according to claim 2 or 3 wherein R1 is methoxy, amino- or guanidino-(C3_5)alkyloxy, guanidino(C3_5)alkyloxy, piperidyl(C3_5)alkyloxy, nitro or fluoro, and Rla is hydrogen.
5. A compound according to any of claims 2 to 4 wherein R-> is in the 3-position and is CH2CO2H or 2-oxo-oxazolidinyl.
6. A compound according to any of claims 2 to 5 wherein AB(CH2)n is (CH2)3-
7. A compound according to any of claims 2 to 6 wherein R4 is (C5. ιo)alkyl, unsubstituted phenyl(C2-3)alkyl or unsubstituted phenyl(C3_4)alkenyl.
8. A compound of formula (I) as defined in claim 1 selected from: [3R, 4R]-l-Heptyl-3-(l-(R or S)-hydroxy-2-cyanoethyl)-4-[3-(6-methoxyquinolin-4- yl)propyl]piperidine ;
[3R, 4R]-l-Heptyl-3-(2-(R or S)-oxo-oxazolidin-5-yl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine;
[3R, 4R]-l-Heptyl-3-(2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine; [3R, 4R]-l-Heptyl-3-(3-carboxyethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine;
[3R, 4R]-l-Heptyl-3-carboxy-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine;
[3R, 4R]-l-Heptyl-3-(carboxymethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine;
[3R, 4R]-l-Heptyl-3-(l-(R or S)-hydroxy-2-carboxyethyl)-4-[3-(6-methoxyquinolin-4- yl)propyl]piperidine; [3R, 4R]- l-Heptyl-3-(2-(E-)-carboxyethenyl)-4-[3-(6-methoxyquinolin-4- yl)propyl]piperidine;
N-(cis-3-(R S)-Εthoxycarbonyl-l-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxyquinolin-4- yl)urea;
N-(cis-3-(R/S)-Ethoxycarbonyl-l-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxy-[l,5]- naphthyridin-4-yl)urea;
N-(cis-3-(R/S)-Aminocarbonyl-l-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxy-[l,5]- naphthyridin-4-yl)urea;
[3R, 4R]-l-Heptyl-4-[3-(R/S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-3-(2-(R or S)- oxo-oxazolidin-5 -yl)-piperidine ; [3R, 4R]- 1 -Heptyl-3-cyanomethyl-4-[3-(R/S)-hydroxy-3-(6-methoxyquinolin-4- yl)propyl]piperidine; [3R, 4R]-l-Heptyl-3-cyanomethyl-4-(2-(R)-hydroxy-3-(6-methoxyquinolin-4- yl)propyl] piperidine ;
N-(cis-3-(R/S)-Carboxy-l-heptyl-4-(S/R)-piperidyl)-N -(6-methoxyquinolin-4-yl)urea; cis-3-(R/S)-Ethoxycarbonyl-l-heptyl-4-(S/R)-(6-methoxyquinolin-4-yl)aminocarbonyl- oxypiperidine; cis-3-(R/S)-Carboxy-l-heptyl-4-(S/R)-(6-methoxyquinolin-4-yl)aminocarbonyl- oxypiperidine; a compound 18-36 from Table 1; or a pharmaceutically acceptable derivative of any of the foregoing compounds.
9. A process for preparing compounds of formula (IA) as defined in claim 2, or a pharmaceutically acceptable derivative thereof, which process comprises:
(a) reacting a compound of formula (IV) with a compound of formula (V):
(IV) (V) wherein Z1, Z2, Z3, Z4 and Z5, m, n, R1, R2, R3 and R4 are as defined in formula (I), and X and Y may be the following combinations: (i) X is M and Y is CH2CO2Rx
(ii) X is CO2Ry and Y is CH2CO2Rx
(iii) one of X and Y is CH=SPh2 and the other is CHO
(iv) X is CH3 and Y is CHO
(v) X is CH3 and Y is CO2Rx (vi) X is CH2CO2Ry and Y is CO2Rx
(vii) X is CH=PRZ 3 and Y is CHO
(viii) X is CHO and Y is CH=PRZ 3
(ix) X is halogen and Y is CH=CH2
(x) one of X and Y is COW and the other is NHR 1 1 ' or NCO (xi) one of X and Y is (CH2)p-N and the other is (CH2)qΝHR 11 ', (CH2)qOH,
(CH2)qSH or (CH2)qSCORx where p+q=l
(xii) one of X and Y is CHO and the other is NHR11 '
(xiii) one of X and Y is OH and the other is -CH=N2 in which V and W are leaving groups, Rx and Ry are (Cι_6)alkyl and Rz is aryl or (C\.
6)alkyl, or
(xiv) X is NCO, Y is OH or NH2 ;
(b) reacting a compound of formula (IV) with a compound of formula (Vb):
(IV) (Nb) wherein Z1, Z2, Z3, Z4 and Z5, m, n, R1, R2, R3 and R4 are as defined in formula (I), X is CH2NHR11 ' and Y is CHO or COW or X is CH2OH and Y is -CH=N2;
(c) rearranging a compound of formula (II):
to give a compound of formula (HI) which is a compound of formula (I) where Z^Z^ are
CH, n is 1, A-B is COCH2 and R2 is H, or a compound of formula (VII) which is a compound of formula (I) where n is 1, A-B is CHOHCH2 or CH2CHOH and R2 is H; or
(d) photooxygenating a compound of formula (VI):
in which Z1 -Z^' are Z1^ or groups convertible thereto, R11 , R1', R2', R3' and R4' are R1 !, R1, R2, R3 and R4 or groups convertible thereto, and thereafter optionally or as necessary converting R1 1 ', R1 ', R2', R3' and R4' to R1 1 ', R1 , R2, R3 and R4, converting Zi'-ZS' to Zi-Z5, converting A-B to other A-B, interconverting R1 1, R1, R2, R3 and/or R4 and forming a pharmaceutically acceptable derivative thereof.
10. A pharmaceutical composition comprising a compound of formula (IA) as defined in claim 2, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
11. The use of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.
12. A pharmaceutical composition for use in the treatment of bacterial infections in mammals comprising a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
EP00902605A 1999-01-20 2000-01-17 Piperidinylquinolines as protein tyrosine kinase inhibitors Withdrawn EP1144404A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9901236 1999-01-20
GBGB9901236.1A GB9901236D0 (en) 1999-01-20 1999-01-20 Medicaments
GB9923936 1999-10-08
GBGB9923936.0A GB9923936D0 (en) 1999-10-08 1999-10-08 Compounds
PCT/EP2000/000350 WO2000043383A1 (en) 1999-01-20 2000-01-17 Piperidinylquinolines as protein tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
EP1144404A1 true EP1144404A1 (en) 2001-10-17

Family

ID=26315007

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00902605A Withdrawn EP1144404A1 (en) 1999-01-20 2000-01-17 Piperidinylquinolines as protein tyrosine kinase inhibitors

Country Status (4)

Country Link
EP (1) EP1144404A1 (en)
JP (1) JP2002535323A (en)
AU (1) AU2437900A (en)
WO (1) WO2000043383A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
US6403610B1 (en) 1999-09-17 2002-06-11 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them
FR2798656B1 (en) * 1999-09-17 2004-12-17 Aventis Pharma Sa DERIVATIVES OF QUINOLYL PROPYL PIPERIDINE, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
US6803369B1 (en) 2000-07-25 2004-10-12 Smithkline Beecham Corporation Compounds and methods for the treatment of neoplastic disease
AU8974901A (en) 2000-07-26 2002-02-05 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
FR2816618B1 (en) * 2000-11-15 2002-12-27 Aventis Pharma Sa HETEROCYCLYLALCOYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
GB0031086D0 (en) * 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
FR2822154B1 (en) * 2001-03-13 2005-10-21 Aventis Pharma Sa QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
US6602884B2 (en) 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) * 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
US7109213B2 (en) 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
EP2181996A1 (en) 2002-01-29 2010-05-05 Glaxo Group Limited Aminopiperidine derivatives
AR040335A1 (en) 2002-06-26 2005-03-30 Glaxo Group Ltd CYCLLOHEXAN OR CYCLHEXENE COMPOUND, USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE AND INTERMEDIATE COMPOUNDS OF UTILITY TO PREPARE SUCH COMPOUND
AR040336A1 (en) 2002-06-26 2005-03-30 Glaxo Group Ltd PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE SUCH COMPOUND
FR2842807A1 (en) 2002-07-23 2004-01-30 Aventis Pharma Sa QUINOLYL PROPYL PIPERIDINE DERIVATIVES, PROCESS AND PREPARATION INTERMEDIATES AND COMPOSITIONS COMPRISING THE SAME
GB0217294D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (en) * 2002-09-11 2004-10-22 Aventis Pharma Sa QUINOLYL PROPYL PIPERIDINE DERIVATIVES, PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION, AND COMPOSITIONS CONTAINING THEM
FR2844270B1 (en) * 2002-09-11 2006-05-19 Aventis Pharma Sa QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THEIR PROCESS AND PREPARATION INTERMEDIATES AND THE COMPOSITIONS CONTAINING THEM
US6835841B2 (en) 2002-09-13 2004-12-28 Bristol-Myers Squibb Company Asymmetric catalytic hydrogenation process for preparation of chiral cyclic β-aminoesters
EP1560821B8 (en) 2002-11-05 2010-05-19 Glaxo Group Limited Antibacterial agents
JP2006515862A (en) 2002-12-04 2006-06-08 グラクソ　グループ　リミテッド Quinolines and their nitrogenated derivatives and their use as antibacterial agents
ES2563304T3 (en) 2003-04-24 2016-03-14 Incyte Holdings Corporation Azaespiro alkane derivatives as metalloprotease inhibitors
UA86952C2 (en) 2004-01-23 2009-06-10 Янссен Фармацевтика Н.В. Quinoline derivatives and use thereof as mycobacterial inhibitors
FR2867472B1 (en) * 2004-03-12 2008-07-18 Aventis Pharma Sa QUINOLINE-4-SUBSTITUTED DERIVATIVES, METHODS AND PREPARATION INTERMEDIATES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2872164B1 (en) * 2004-06-29 2006-11-17 Aventis Pharma Sa QUINOLINE-4-SUBSTITUTED DERIVATIVES, PROCESS AND PREPARATION INTERMEDIATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2006038172A1 (en) * 2004-10-05 2006-04-13 Actelion Pharmaceuticals Ltd New piperidine antibiotics
EP1846418A4 (en) 2005-01-25 2009-12-23 Glaxo Group Ltd Antibacterial agents
EP1846417A4 (en) 2005-01-25 2009-12-23 Glaxo Group Ltd Antibacterial agents
EP1846411A4 (en) 2005-01-25 2010-08-04 Glaxo Group Ltd Antibacterial agents
WO2006081179A1 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2006081178A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
ES2430569T3 (en) * 2005-02-18 2013-11-21 Astrazeneca Ab Piperidine-derived antibacterial compounds
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2007086016A1 (en) 2006-01-26 2007-08-02 Actelion Pharmaceuticals Ltd Tetrahydropyrane antibiotics
EP2007377A4 (en) 2006-04-06 2011-08-17 Glaxo Group Ltd Antibacterial agents
EP2155716A2 (en) * 2007-05-09 2010-02-24 Pfizer Inc. Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
WO2016138988A1 (en) * 2015-03-02 2016-09-09 University Of Copenhagen Piperazine inhibitors of bacterial gyrase and topoisomerase iv

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
AU757059B2 (en) * 1997-06-19 2003-01-30 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
JP2002501061A (en) * 1998-01-26 2002-01-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Quinoline derivatives for antibacterial agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0043383A1 *

Also Published As

Publication number Publication date
JP2002535323A (en) 2002-10-22
AU2437900A (en) 2000-08-07
WO2000043383A1 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
WO2000043383A1 (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
US6989447B2 (en) Compounds
EP1127057B1 (en) Naphthyridine compounds and thier azaisosteric analogues as antibacterials
EP1214314B1 (en) Aminopiperidine derivatives as antibacterials
EP1187828B1 (en) Quinoline derivatives as antibacterials
US6602882B1 (en) Quinoline derivatives and their use as antibacterial agents
EP1343765B1 (en) Quinolines and nitrogenated derivatives thereof substituted in 4-position by a piperazine-containing moiety and their use as antibacterial agents
JP4508650B2 (en) Aminopiperidine compound, process for producing the compound and pharmaceutical composition containing the compound
US20040053928A1 (en) Quinoline derivatives as antibacterials
JP4445753B2 (en) Aminopiperidine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010712

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071103